Track market-moving stories before they get noisy

Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of International Flavors & Fragrances Inc. (NYSE:IFF – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 182,640 shares of the specialty chemicals company’s stock, valued at approximately $14,469,000. Barrow Hanley Mewhinney & Strauss LLC owned about 0.07% of International Flavors & Fragrances at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. BlackRock Inc. bought a new stake in International Flavors & Fragrances during the second quarter worth approximately $1,835,955,000. Invesco Ltd. increased its holdings in shares of International Flavors & Fragrances by 131.3% during the 3rd quarter. Invesco Ltd. now owns 7,167,176 shares of the specialty chemicals company’s stock worth $441,068,000 after purchasing an additional 4,069,075 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in International Flavors & Fragrances in the 4th quarter valued at approximately $211,703,000. Ameriprise Financial Inc. raised its stake in shares of International Flavors & Fragrances by 1,842.0% in the second quarter. Ameriprise Financial Inc. now owns 2,491,606 shares of the specialty chemicals company’s stock valued at $183,264,000 after purchasing an additional 2,363,307 shares in the last quarter. Finally, First Eagle Investment Management LLC lifted its holdings in shares of International Flavors & Fragrances by 27.5% during the 4th quarter. First Eagle Investment Management LLC now owns 8,831,668 shares of the specialty chemicals company’s stock worth $595,166,000 after acquiring an additional 1,904,598 shares during the period. Institutional investors and hedge funds own 96.02% of the company’s stock.

Insider Buying and Selling at International Flavors & Fragrances In other news, Director Paul J. Fribourg purchased 260,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $74.28 per share, with a total value of $19,312,800.00. Following the purchase, the director owned 2,682,730 shares in the company, valued at approximately $199,273,184.40. This trade represents a 10.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider De Mendonca Ana Paula Teles sold 5,718 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $83.19, for a total transaction of $475,680.42. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,543 shares of company stock worth $1,315,659 over the last quarter. Company insiders own 1.07% of the company’s stock.

International Flavors & Fragrances Stock Performance Shares of IFF stock opened at $84.31 on Monday. International Flavors & Fragrances Inc. has a 12 month low of $59.14 and a 12 month high of $89.32. The stock has a market capitalization of $21.51 billion, a P/E ratio of 77.35, a PEG ratio of 3.12 and a beta of 0.93. The company has a current ratio of 2.06, a quick ratio of 1.72 and a debt-to-equity ratio of 0.34. The firm’s 50 day moving average is $79.56 and its 200 day moving average is $76.34. International Flavors & Fragrances (NYSE:IFF – Get Free Report) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.25). International Flavors & Fragrances had a return on equity of 7.11% and a net margin of 2.78%.The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter last year, the firm posted $1.15 earnings per share. The firm’s revenue was up 1.8% on a year-over-year basis. On average, sell-side analysts anticipate that International Flavors & Fragrances Inc. will post 3.08 earnings per share for the current year.

International Flavors & Fragrances declared that its Board of Directors has authorized a stock buyback program on Tuesday, August 4th that authorizes the company to buyback $2.50 billion in shares. This buyback authorization authorizes the specialty chemicals company to reacquire up to 12.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

International Flavors & Fragrances Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 9th. Shareholders of record on Friday, September 18th will be paid a dividend of $0.40 per share. The ex-dividend date is Friday, September 18th. This represents a $1.60 dividend on an annualized basis and a yield of 1.9%. International Flavors & Fragrances’s payout ratio is currently 146.79%.

Here are the key news stories impacting International Flavors & Fragrances this week:

Positive Sentiment: IFF is trading above its 50-day and 200-day moving averages and near its 52-week high, signaling continued investor momentum even though the latest reports do not identify a new fundamental catalyst. Positive Sentiment: The company authorized a $2.5 billion share-repurchase program, potentially covering up to 12.1% of outstanding shares. The buyback may support earnings per share and suggests management believes the stock is undervalued. Positive Sentiment: Institutional ownership remains high at approximately 96%, while several large investors—including BlackRock, Invesco and Ameriprise—recently increased or initiated positions. IFF also declared a quarterly dividend of $0.40 per share. Neutral Sentiment: CEO Erik Fyrwald is scheduled to participate in a Barclays Global Consumer Conference fireside chat on September 10. Investors may look for updates on strategy, operating performance and capital allocation, but no new guidance has been provided. IFF Barclays conference announcement Negative Sentiment: Zacks Research repeatedly lowered its EPS forecasts and maintained a “Strong Sell” rating. FY2026 EPS was cut to $3.14 from $4.45, FY2027 to $3.71 from $4.81, and FY2028 to $4.31 from $5.21. The revisions indicate expectations for weaker profitability over multiple years. Negative Sentiment: The largest near-term reduction was for Q3 2026 EPS, lowered to $0.67 from $1.14. Estimates for Q4 2026 and each quarter of 2027 were also reduced, raising concerns about sustained earnings pressure and IFF’s elevated valuation. Negative Sentiment: An insider sold 5,718 shares for approximately $476,000 at an average price of $83.19. One transaction is not conclusive, but it provides a modest negative signal for investors monitoring insider confidence. IFF insider sale report Negative Sentiment: IFF’s latest reported quarter missed analyst expectations, with EPS of $0.82 versus $1.07 expected and revenue of $1.95 billion versus $2.62 billion expected, reinforcing concerns behind the estimate cuts. Analyst Ratings Changes Several brokerages have recently commented on IFF. Oppenheimer boosted their target price on International Flavors & Fragrances from $88.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Vertical Research downgraded shares of International Flavors & Fragrances from a “buy” rating to a “hold” rating and set a $93.00 price objective on the stock. in a report on Thursday, August 6th. Citigroup cut their target price on shares of International Flavors & Fragrances from $96.00 to $88.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. Berenberg Bank lifted their price objective on shares of International Flavors & Fragrances from $83.00 to $84.80 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Finally, UBS Group boosted their price target on International Flavors & Fragrances from $84.00 to $91.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.16.

Read Our Latest Stock Report on IFF

About International Flavors & Fragrances (Free Report)

International Flavors & Fragrances Inc (NYSE:IFF) is a global leader in the creation and production of flavors, fragrances, cosmetic actives and nutritional lipids. The company develops taste and scent solutions for a wide array of end markets including food and beverage, personal care, household goods and pharmaceutical products. Its portfolio spans natural and nature-identical flavors, fine fragrances, functional ingredients for skin and hair care, and specialty oils that enhance nutritional value and sensory appeal.

IFF’s research and development network comprises innovation centers in North America, Europe, Asia-Pacific and Latin America, where multidisciplinary teams collaborate on aroma chemistry, sensory science and biotechnology.

Recommended Stories Five stocks we like better than International Flavors & Fragrances VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for International Flavors & Fragrances Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Flavors & Fragrances and related companies with MarketBeat.com's FREE daily email newsletter.

Latest credit of over $6 brings total settlement refunds to nearly $37 per customer while the company continues PFAS treatment upgrades across Pennsylvania

, /PRNewswire/ -- Pennsylvania American Water announced that additional credits were recently applied to customers' bills as a result of the company's receipt of proceeds from settlements reached with manufacturers of per- and polyfluoroalkyl substances (PFAS).

On July 27, 2026, Pennsylvania American Water issued a $6.13 bill credit to all active water customer accounts as of July 24, 2026. The credit distributes recent settlement proceeds the company received from PFAS manufacturers to customers.

The credit is made possible through Pennsylvania Public Utility Commission (PUC) approval of Pennsylvania American Water's PFAS Litigation Universal Credit Rider, which allows the company to provide PFAS settlement proceeds directly to customers as they are received. Including this latest credit, customers have received a total of $36.89 per account from PFAS-related settlements to date.

The company remains in compliance with all PFAS drinking water standards and has completed PFAS treatment upgrades in several communities and plans to spend approximately $321 million to expand PFAS treatment across multiple water systems throughout Pennsylvania. For more information about PFAS and the steps Pennsylvania American Water is taking to address them, visit our PFAS information page.

About American Water 
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 19 military installations. American Water's approximately 7,000 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram. 

About Pennsylvania American Water 
Pennsylvania American Water, a subsidiary of American Water, is the largest regulated water utility in the state with approximately 1,200 dedicated employees working to provide safe, clean, reliable and affordable water and wastewater services to approximately 2.5 million people.

SOURCE American Water

BlackRock Inc. bought a new position in shares of National Health Investors, Inc. (NYSE:NHI – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,733,237 shares of the real estate investment trust’s stock, valued at approximately $665,997,000. BlackRock Inc. owned 18.02% of National Health Investors as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC bought a new position in shares of National Health Investors during the 4th quarter valued at about $27,000. EverSource Wealth Advisors LLC raised its holdings in shares of National Health Investors by 244.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 406 shares of the real estate investment trust’s stock worth $28,000 after purchasing an additional 288 shares in the last quarter. Garton & Associates Financial Advisors LLC bought a new stake in National Health Investors during the fourth quarter worth approximately $33,000. Advisory Services Network LLC bought a new stake in National Health Investors during the third quarter worth approximately $65,000. Finally, Triumph Capital Management acquired a new position in National Health Investors in the third quarter worth approximately $66,000. 62.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets Several research analysts have issued reports on NHI shares. BMO Capital Markets dropped their price target on National Health Investors from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Monday, June 15th. Zacks Research cut National Health Investors from a “hold” rating to a “strong sell” rating in a report on Thursday, June 25th. Wells Fargo & Company cut their target price on National Health Investors from $84.00 to $79.00 and set an “equal weight” rating on the stock in a research report on Monday, June 1st. Weiss Ratings downgraded National Health Investors from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, June 12th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on National Health Investors from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, June 25th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.86.

Check Out Our Latest Research Report on National Health Investors Insider Transactions at National Health Investors In related news, CEO D. Eric Mendelsohn purchased 1,500 shares of National Health Investors stock in a transaction dated Friday, June 5th. The stock was acquired at an average cost of $68.84 per share, with a total value of $103,260.00. Following the completion of the transaction, the chief executive officer directly owned 133,316 shares of the company’s stock, valued at $9,177,473.44. This trade represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert A. Mccabe, Jr. purchased 890 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were bought at an average price of $71.65 per share, with a total value of $63,768.50. Following the completion of the acquisition, the director owned 44,159 shares of the company’s stock, valued at $3,163,992.35. This trade represents a 2.06% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 2.70% of the company’s stock.

National Health Investors Trading Up 0.3% National Health Investors stock opened at $73.59 on Monday. National Health Investors, Inc. has a 52 week low of $67.94 and a 52 week high of $91.38. The company has a debt-to-equity ratio of 0.81, a quick ratio of 6.78 and a current ratio of 6.78. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of 21.27, a P/E/G ratio of 3.36 and a beta of 0.51. The company has a 50 day moving average price of $75.48 and a 200 day moving average price of $79.09.

National Health Investors (NYSE:NHI – Get Free Report) last released its earnings results on Monday, August 10th. The real estate investment trust reported $1.19 earnings per share (EPS) for the quarter. National Health Investors had a return on equity of 10.89% and a net margin of 38.56%.The company had revenue of $121.32 million during the quarter. During the same quarter in the previous year, the company earned $1.22 EPS. National Health Investors’s revenue for the quarter was up 1.6% on a year-over-year basis. National Health Investors has set its FY 2026 guidance at 4.740-4.790 EPS. Research analysts forecast that National Health Investors, Inc. will post 4.78 EPS for the current year.

National Health Investors Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 6th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.92 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.68 dividend on an annualized basis and a yield of 5.0%. National Health Investors’s dividend payout ratio (DPR) is presently 108.67%.

National Health Investors Company Profile (Free Report)

National Health Investors, Inc (NYSE: NHI) is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company’s portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.

Featured Articles Five stocks we like better than National Health Investors VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding NHI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National Health Investors, Inc. (NYSE:NHI – Free Report).

Receive News & Ratings for National Health Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Health Investors and related companies with MarketBeat.com's FREE daily email newsletter.

Deutsche Bank AG acquired a new position in shares of Chemed Corporation (NYSE:CHE – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,747 shares of the company’s stock, valued at approximately $7,800,000. Deutsche Bank AG owned about 0.13% of Chemed at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its holdings in shares of Chemed by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 734 shares of the company’s stock worth $314,000 after purchasing an additional 22 shares during the period. Cim LLC increased its position in shares of Chemed by 1.1% during the 3rd quarter. Cim LLC now owns 2,139 shares of the company’s stock valued at $958,000 after purchasing an additional 24 shares during the last quarter. Eukles Asset Management raised its holdings in Chemed by 0.4% during the 4th quarter. Eukles Asset Management now owns 6,056 shares of the company’s stock valued at $2,591,000 after buying an additional 25 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Chemed by 65.3% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after buying an additional 32 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Chemed by 9.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after buying an additional 35 shares during the period. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Trading Up 0.1% Shares of NYSE CHE opened at $541.33 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The business’s 50 day moving average price is $499.24 and its 200-day moving average price is $446.50. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $557.00. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 27.19, a PEG ratio of 2.05 and a beta of 0.51.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The company had revenue of $673.25 million during the quarter, compared to analysts’ expectations of $665.04 million. During the same quarter in the previous year, the business earned $4.27 EPS. Chemed’s revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, sell-side analysts expect that Chemed Corporation will post 23.18 earnings per share for the current year. Chemed Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is a positive change from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date is Monday, August 17th. Chemed’s dividend payout ratio is 14.06%.

Analyst Ratings Changes CHE has been the subject of several recent analyst reports. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Royal Bank Of Canada raised their target price on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Oppenheimer lifted their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $530.75.

View Our Latest Research Report on CHE

Insider Transactions at Chemed In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer directly owned 70,418 shares of the company’s stock, valued at approximately $37,991,215.18. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the transaction, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,537 shares of company stock worth $1,782,654. 3.33% of the stock is currently owned by insiders.

Chemed Profile (Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Featured Articles Five stocks we like better than Chemed VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

At $183.99, KLA Corporation (NASDAQ:KLAC | KLAC Price Prediction) looks compelling at current levels. The stock has fallen 14.2% over the past month even as management raised its outlook on the two fastest-growing corners of the semiconductor equipment market, creating a rare dislocation in a stock that rarely goes on sale.

KLA sells the inspection, metrology, and process-control tools that chipmakers rely on to keep yields high as transistor geometries shrink. Management says the company runs at roughly 6x its nearest rival in overall process-control share, giving it a near-monopoly position on a segment that grows faster than the underlying market as complexity rises.

The pullback traces to renewed anxiety about U.S. export controls on China and a broad rotation out of semi-cap names, not to any deterioration in the business. Fiscal Q4 revenue reached $3.66 billion, up 15.21% year over year, with non-GAAP EPS of $1.05 beating expectations, the fifth consecutive beat.

Why the Dip Looks Like an Invitation Management raised its calendar 2026 wafer-equipment market outlook to the low $150 billion range and lifted advanced-packaging systems revenue guidance to roughly $1.1 billion, growth of more than 70% year over year. CEO Rick Wallace said “momentum across our business accelerating in the second half of calendar 2026 and continuing through 2027.”

The service business anchors the model. Services revenue hit $820 million, up 17% year over year, with roughly 80% under contract. Fabs must run inspection tools around the clock regardless of the equipment cycle, which softens downturns. Capital intensity per wafer also rises at each successive node, so process-control spend expands faster than baseline WFE growth. Shares trade at a 34 forward P/E, well below the 50 trailing multiple as earnings scale into guidance.

Where the Bear Case Bites KLA carries real China risk. Management acknowledged that competitors have shifted into fabs in China KLA cannot serve, and any tightening of Bureau of Industry and Security rules would compress the addressable market. Gross margin of 62.4% is absorbing tariff headwinds and memory-pricing pressure that may persist through 2027.

Insider activity adds caution. In August, the CEO, CFO, and multiple executive officers executed sizable open-market disposals, including a 87,568-share sale by Wallace at $198.95. Free cash flow slipped, with Q4 FCF of $817 million, down 23.24% year over year as working capital funds the ramp.

Reasons to Wait KLA is not obviously cheap. A 17.7 price-to-sales ratio and 38 price-to-book leave little margin for a cyclical stumble. With shares up 51.99% year to date and 112.04% over one year, a patient investor could wait for the September quarter print to confirm the accelerating second-half thesis before committing.

What the Numbers Say KLAC trades at $183.99 against a consensus analyst target of $231.78, implying meaningful upside. Coverage skews constructive, with 5 strong buy, 13 buy, 11 hold, and 0 sell ratings across 29 analysts.

KLAC is up 51.99% year to date while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) has moved from 729.46 at the Q4 filing to 765.72 currently. Shares sit well below the 50-day moving average of $220.07 and closer to the 200-day of $168.52.

Why the Selloff Is the Opportunity At $183.99, the setup looks attractive. Q1 FY2027 guidance calls for revenue of $4.0 billion plus or minus $200 million and non-GAAP EPS of $1.16 plus or minus $0.10. Management expects second-half calendar 2026 growth of roughly 20% over the first half, with backlog around $12.5 billion.

The risk/reward at a 34 forward P/E favors buyers. Advanced packaging alone is expected to grow almost two times faster than the market, and HBM plus EUV-driven DRAM intensity should carry process-control demand into calendar 2027. The company returned $876.33 million to shareholders in Q4 and just added a $7 billion buyback authorization.

What would invalidate the thesis: a broader China export-control escalation that cuts guidance, or a September-quarter miss that breaks the beat streak. Absent that, the setup pairs an accelerating end market with a stock trading nearly 40% below its 52-week high of $307.03. Buying the dominant process-control franchise during an AI capex acceleration, at a discount to its own recent multiple, is a research-worthy setup at this price.

Contact [email protected] for any questions or corrections.

Semiconductor giant Broadcom NASDAQ: AVGO has seen its share price take a significant tumble over recent weeks, with custom AI chip diversification being a key investor concern.

Broadcom Today

$362.16 -6.29 (-1.71%)

As of 10:25 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$287.17▼

$495.000.72%

60.43

$491.97

Compared to a recent high of about $428, Broadcom shares have fallen by more than 10%. This is somewhat attributable to general AI semiconductor weakness, with NVIDIA NASDAQ: NVDA down moderately over the same period. However, news surrounding the company’s biggest customer and a top custom chip competitor has accelerated the decline in Broadcom stock.

Get Broadcom alerts:

Alphabet NASDAQ: GOOGL subsidiary Google is well known as Broadcom’s largest and longest-standing buyer of custom AI chips. Marvell Technology NASDAQ: MRVL has thrown a bit of a wrench into this equation, signing its own deal with Google to develop custom semiconductor products. Furthermore, Marvell isn’t the only chip company threatening Broadcom’s position, making its upcoming earnings report a key opportunity to restore investor confidence.

Marvell and Google Enter Custom Chip CollaborationA recent Marvell SEC filing states that at the end of July, it “entered into a commercial agreement relating to the Company’s development of custom semiconductor products to Google.” It notes that the partnership “spans a comprehensive range of custom silicon programs that attach to the TPU ecosystem, including AI inference accelerators, storage controllers, network interface controllers, memory interface controllers, and near-memory compute.”

Some have characterized this as Broadcom effectively losing share within Google’s Tensor Processing Unit (TPU) development pipeline. However, it is important to note that the wording of Marvell’s filing is more ambiguous. Marvell references “custom silicon programs that attach to the TPU ecosystem” rather than saying that it will outright develop TPUs.

Still, its programs with Google include “AI inference accelerators," which aligns with Google’s description of chips like its TPU 8i. In this sense, Marvell may be developing chips that serve a similar purpose as inference TPUs, which could effectively erode Broadcom’s AI chip share at Google.

Despite this, it is key to note that Broadcom signed a TPU and networking deal through 2031 with Google in April. This deal demonstrates that Broadcom is likely to remain a key Google TPU partner for years to come.

On the other hand, the Marvell and Google deal includes potential equity investments that could tie the firms closer together and indicate that the size of their relationship could become massive.

Marvell Warrant Structure Indicates a Huge Revenue OpportunityMarvell has issued warrants to Google that allow it to buy nearly 59 million shares of Marvell stock. With approximately 876 million shares outstanding, exercising all of these warrants would give Google over 6% ownership in Marvell. This economic alignment could give Google an added interest in directing business to Marvell. In turn, Google’s spending at Broadcom could suffer.

However, the second part of the warrant structure is more notable. The majority of the warrants vest only after Google makes discretionary purchases of custom products. They vest in 240 equally sized tranches, with each tranche requiring $500 million in product purchases. In turn, Google would need to make $120 billion in cumulative purchases from Marvell to gain access to all of the warrants.

Google has from Marvell’s fiscal Q3 2027 through the end of its fiscal year 2033 to make these purchases. (Note that Marvell’s fiscal reporting period is several quarters ahead of the calendar period, with the company currently in its fiscal Q2 2027.)

The incredible size of this figure makes it difficult to believe it will fully materialize. For reference, $120 billion is more than 13 times higher than Marvell’s last 12 months' revenue of $8.7 billion—and over 11 times higher than all of Broadcom’s $10.8 billion in AI semiconductor revenue last quarter. Nonetheless, it highlights that the Marvell-Google relationship could be very material.

Still, there is no clean dollar figure that provides a baseline of how large Marvell’s relationship with Google could be. This makes it difficult to assess how much of a negative impact the deal could have on Broadcom.

The deal is another clear signal that custom chip competition is intensifying, particularly around Google’s TPUs. Analysts believe that MediaTek OTCMKTS: MDTKF is one of Google’s alternate TPU partners. Meanwhile, rumors have surfaced that Advanced Micro Devices NASDAQ: AMD is working with Google on future TPU generations. For the incumbent leader, Broadcom, it is difficult to see these developments as anything but negative.

AI Chip Guidance Increase Could Get Investors Back on Broadcom’s SideAmid this increased level of competition, there is one particularly powerful lever that Broadcom could pull to quell investor fears: raising its guidance. Broadcom’s decision not to raise its fiscal year 2027 AI semiconductor revenue guidance was one of the main reasons shares tanked after its latest earnings report. (Note that Broadcom’s fiscal reporting period is ahead of the calendar period, with the company currently in its fiscal Q3 2026.)

Broadcom Inc. (AVGO) Price Chart for Monday, August, 24, 2026

There is reason to believe Broadcom was simply being conservative. However, intensifying competition, highlighted by the Marvell-Google deal, raises concerns. Could Broadcom be uncertain about its growth prospects because of this, leading it to not increase guidance? Questions like these are likely swirling in investors' minds.

Raising its 2027 guidance significantly could go a long way in putting these fears to bed, although it would not dispel general competition concerns. This makes Broadcom’s fiscal year 2027 AI semiconductor guidance likely the biggest factor to watch in its upcoming earnings report.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Broadcom Right Now?Before you consider Broadcom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Broadcom wasn't on the list.

While Broadcom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Key Takeaways Quanta Services raised 2026 revenue and EPS guidance as backlog reached a record $53.4 billion. Comfort Systems USA's backlog jumped 73.2% year over year, driven by AI data center construction strength.Both companies expect strong 2026 growth, with brokerage targets indicating substantial potential upside. The artificial intelligence (AI) frenzy remains intact as the AI infrastructure space remains rock solid, supported by an extremely bullish demand scenario. Here, we have narrowed our search to two Zacks top-ranked AI-powered construction giants that have posted solid second-quarter 2026 earnings results and guidance. These stocks have flourished year to date, yet they have solid upside potential for the short term. 

The stocks are: Quanta Services Inc. (PWR - Free Report) and Comfort Systems USA Inc. (FIX - Free Report) . Each of our picks currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The chart below shows the price performance of our two picks year to date.

Image Source: Zacks Investment Research

Quanta Services Inc.Quanta Services is well-positioned to capitalize on robust infrastructure spending across utility, power generation, technology and load center markets. The ongoing expansion of AI data centers, grid modernization, renewable generation and advanced manufacturing is driving customers to undertake larger, multiyear infrastructure programs.

Surging AI-related power demand and expanding utility investments are driving data center project opportunities, making data centers a central pillar of PWR’s long-term growth strategy. The company is heavily investing in deepening its vertical supply chain to offset the ongoing global uncertainties and rising inflation. 

PWR expects to invest $500-$700 million over the next several years in power transformer manufacturing facilities and related strategy, which is intended to double transformer manufacturing capacity.

Long-Term ProspectsPWR is well-positioned to capitalize on robust infrastructure spending across utility, power generation, technology and load center markets. Management believes that the company is still in the early stages of the current demand cycle, with larger utility-generation and technology/load center programs expected to be built over the coming years.

These favorable trends helped drive total backlog to a record $53.4 billion as of June 30, 2026, up 49% year over year from $35.8 billion in June 2025. The increase was broad-based, with Electric Infrastructure Solutions backlog rising year over year to $43.8 billion from $30.3 billion, while Underground and Infrastructure Solutions backlog climbed to $9.7 billion from $5.6 billion.

Strong GuidanceQuanta raised full-year 2026 expectations. Management forecasts consolidated revenues of $39.3-$39.7 billion (compared with the prior expectations of $34.7-$35.2 billion) and adjusted EPS of $16.45-$16.95 (compared with the earlier projection of $13.55-$14.25). Adjusted EBITDA is projected in the range of $4.09-$4.21 billion, up from the earlier expectation of $3.49-$3.65 billion.

Solid Estimate RevisionsQuanta has an expected revenue and earnings growth rate of 38.4% and 52.3%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 16.8% over the last 30 days. 

PWR has an expected revenue and earnings growth rate of 14.9% and 15.8%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 15.4% over the last 30 days. 

Image Source: Zacks Investment Research

Impressive Price Upside PotentialThe short-term average price target of brokerage firms represents an increase of 26.7% from the last closing price of $639.34. The brokerage target price is currently in the range of $690-$976. This indicates a maximum upside of 52.7% and no downside. 

Comfort Systems USA Inc.Comfort Systems operates primarily in the commercial and industrial heating, ventilation and air conditioning (HVAC) markets. The data center boom, driven by AI, cloud computing, and high-performance computing, is fueling demand for specialized HVAC solutions from FIX. 

Cooling systems for these facilities should deliver precise and reliable performance, prompting investments in advanced technologies such as liquid cooling and modular units. This segment is becoming a significant growth driver for FIX, offering high-margin growth and attracting M&A activity. HVAC firms with capabilities in precision cooling and energy-efficient infrastructure are well-positioned to capture share in this fast-expanding niche. 

Growing BacklogComfort Systems highlighted continued strength in AI-powered data center construction, while industrial customers remained the primary growth engine. Backlog as of June 30, 2026, totaled $14.06 billion, increasing 12.9% from $12.45 billion at March 31, 2026, and jumping 73.2% from $8.12 billion reported a year ago. 

On a same-store basis, backlog climbed to $13.70 billion from $8.12 billion in the year-ago period. FIX guided 2026 same-store revenue growth in the mid- to high-30% range, alongside capital spending of about 5% of revenues.

Strong GuidanceManagement expects faster same-store growth for 2026 and additional modular capacity by late summer 2027. FIX expects same-store revenue growth in the mid- to high-30% range. 

Solid Estimate RevisionsComfort Systems has an expected revenue and earnings growth rate of 38.3% and 58.8%, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 6.6% over the last 30 days. 

FIX has an expected revenue and earnings growth rate of 20% and 26.1%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 9.2% over the last 30 days. 

Image Source: Zacks Investment Research

Excellent Price Upside PotentialThe short-term average price target of brokerage firms represents an increase of 29.3% from the last closing price of $1,655.61. The brokerage target price is currently in the range of $1,910-$2,400. This indicates a maximum upside of 45% and no downside. 

– 17 abstracts and presentations planned at SSIEM Symposium –

– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels –

– Continued evidence of meaningful benefit across all patient subgroups –

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet liberalization and sustained metabolic control for the full spectrum of individuals living with phenylketonuria (PKU) including those with classical PKU. In addition, Sephience studies continue to show a consistent and favorable safety profile.

"The SSIEM presentations further demonstrate the broad clinical benefits of Sephience across the full spectrum of individuals living with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "In addition, new data to be presented at the PTC symposium show treatment with Sephience led to a large number of responsive participants achieving normalization of blood Phe levels (<120 µmol/L) in a rapid timeframe, including those with classical or non-BH4-responsive PKU. These impressive data support the potential benefits Sephience can deliver for individuals affected by PKU."

Highlights of the data to be presented at SSIEM 2026 include:

New analyses from the AMPLIPHY study demonstrate that Sephience treatment resulted in a 100% greater reduction in blood Phe for participants on sapropterin at screening after switching to Sephience. In an analysis of participants in Sephience studies with high baseline Phe levels (≥900 µmol/L), Sephience treatment resulted in clinically meaningful reductions in blood Phe levels within 14 days, with response rates comparable to the overall study population, and a safety profile consistent with prior studies. These findings support a trial of Sephience treatment in individuals with PKU regardless of severity or baseline Phe. An analysis of real-world data performed by a leading global key opinion leader shows that Sephience enabled significant dietary liberalization in adolescents, supporting greater independence, reduced dietary burden, and maintained metabolic control within recommended targets. These results were observed in individuals with both BH4-responsive and classical/non-BH4 responsive PKU mutations. About Sephience™ (sepiapterin)
Sephience™ is indicated for the treatment of adult and pediatric patients with phenylketonuria (PKU). Sephience is a natural precursor of the enzymatic co-factor BH4, a critical co-factor for phenylalanine hydroxylase (PAH). Through its unique dual mechanism of action, Sephience is able to effectively reduce blood phenylalanine (Phe) levels and has the potential to treat a broad range of PKU patients. Sephience is approved in the United States, the European Union/European Economic Area region, Japan and other countries.

Indication and Important Safety Information

Indication
SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)-restricted diet.

Contraindications
None.

Important Safety Information
Treatment with SEPHIENCE should be directed by physicians knowledgeable in the management of PKU. Biochemical response to SEPHIENCE can only be determined by a therapeutic trial with careful monitoring of ongoing dietary and nutritional balance to ensure adequate Phe control.

Warnings and Precautions

Increased Bleeding: SEPHIENCE may increase the risk of bleeding. Bleeding events, including superficial hematomas, prolonged bleeding, and heavy menstrual bleeding have occurred in patients treated with SEPHIENCE. Inform patients about the risk of bleeding associated with SEPHIENCE and have patients follow up with their healthcare provider should such a bleeding event occur. Consider treatment interruption with SEPHIENCE in patients with active bleeding. Hypophenylalaninemia: Some pediatric patients receiving SEPHIENCE experienced hypophenylalaninemia. Monitor blood Phe levels during treatment and modify the dosage of SEPHIENCE and/or dietary protein and Phe intake as needed to ensure adequate blood Phe level control. Frequent blood monitoring is recommended in the pediatric population. Interaction with Levodopa: In a 10-year post-marketing safety surveillance program for a non-PKU indication using another drug that is a phenylalanine hydroxylase (PAH) activator, three patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability during co-administration with levodopa. Monitor patients who are receiving levodopa for changes in neurological status during treatment with SEPHIENCE. Adverse Reactions
Most common adverse reactions with SEPHIENCE (≥2% and > placebo) were diarrhea, headache, abdominal pain, hypophenylalaninemia, feces discoloration and oropharyngeal pain.

Drug Interactions
Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to BH4. If concomitant use is not avoidable, monitor blood Phe levels.

SEPHIENCE and PDE-5 inhibitors (e.g., sildenafil, vardenafil, or tadalafil) induce vasorelaxation and may reduce blood pressure. Monitor for signs and symptoms of hypotension.

For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email [email protected].

You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

About Phenylketonuria
Phenylketonuria (PKU) is a rare, inherited metabolic disease, characterized by the body's inability to break down an essential amino acid called phenylalanine (Phe) and which can result in neurological and other symptoms. If left untreated or poorly managed, Phe can build up to harmful levels in the body. This causes severe and irreversible disabilities, such as permanent intellectual disability, seizures, delayed development, memory loss, and behavioral and emotional problems. Newborns with PKU initially do not have any symptoms, but symptoms are usually progressive, and damage caused by toxic levels of Phe in the first few years of life is irreversible. Diagnosis of PKU usually takes place during newborn screening programs. There are an estimated 58,000 people living with PKU globally.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For More Information: 

Investors:
Ellen Cavaleri
+1 (615) 618-6228
[email protected] 

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected] 

Forward-Looking Statements: 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; expectations with respect to Sephience; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including commercialization and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

SOURCE PTC Therapeutics, Inc.

DVN and Executor Services to Be DeprecatedCross-chain interoperability protocol LayerZero is pulling offchain support from 15 low-activity chains as part of an operational cleanup that takes effect over the next 30 days.

The affected chains named in the announcement include EDU Chain, Meter, Shimmer, Cyber, Silicon, Sophon, Bitlayer, Degen, Arbitrum Nova, and Cronos zkEVM, among others.

In other words, the core protocol itself remains intact, but operators relying on LayerZero Labs' own infrastructure on these chains will lose those routes once the transition is complete.

Stargate Users Urged to Act Before DeadlineThe deprecation also has direct consequences for Stargate users.

The move reads as routine housekeeping rather than a retreat from the protocol's core, since the affected chains carried minimal volume to begin with. Still, anyone holding assets on the named networks should treat the 30-day window as urgent.

Sources:
LayerZero Official Support Update | CryptoAdventure: LayerZero DVN and Executor Deprecation | AMBCrypto: LayerZero Chain Wind-Down Details

Great Lakes Advisors LLC purchased a new stake in shares of Matador Resources Company (NYSE:MTDR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,162 shares of the energy company’s stock, valued at approximately $605,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Altshuler Shaham Ltd raised its position in Matador Resources by 36.7% in the 1st quarter. Altshuler Shaham Ltd now owns 748 shares of the energy company’s stock worth $47,000 after purchasing an additional 201 shares during the last quarter. Burford Brothers Inc. boosted its position in Matador Resources by 0.8% in the 1st quarter. Burford Brothers Inc. now owns 26,798 shares of the energy company’s stock valued at $1,693,000 after buying an additional 225 shares during the last quarter. Fiduciary Trust Co boosted its position in Matador Resources by 2.2% in the 3rd quarter. Fiduciary Trust Co now owns 11,821 shares of the energy company’s stock valued at $531,000 after buying an additional 253 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its position in Matador Resources by 2.9% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 9,138 shares of the energy company’s stock valued at $388,000 after buying an additional 254 shares during the last quarter. Finally, Verdence Capital Advisors LLC increased its stake in shares of Matador Resources by 3.5% in the 4th quarter. Verdence Capital Advisors LLC now owns 8,233 shares of the energy company’s stock valued at $349,000 after buying an additional 278 shares during the period. Institutional investors and hedge funds own 91.98% of the company’s stock.

Analyst Ratings Changes A number of research firms have recently weighed in on MTDR. Mizuho upgraded Matador Resources to a “strong-buy” rating in a research report on Friday, July 31st. Citigroup decreased their price target on Matador Resources from $68.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. UBS Group lifted their price objective on Matador Resources from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Monday, August 10th. Stephens boosted their price objective on Matador Resources from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Finally, Roth Capital raised Matador Resources from a “neutral” rating to a “buy” rating and set a $65.00 price objective for the company in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.07.

Read Our Latest Stock Report on Matador Resources More Matador Resources News Here are the key news stories impacting Matador Resources this week:

Positive Sentiment: CEO Joseph Wm. Foran purchased another 400 shares at an average price of $53.64, increasing his stake by 1.31%. The purchase follows several additional buys earlier in August, signaling management confidence in Matador’s valuation and outlook. Matador Resources CEO Purchases 400 Shares of Stock Positive Sentiment: Matador’s latest quarterly results were stronger than expected: earnings per share came in at $2.61 versus the $2.08 consensus estimate, while revenue reached $1.17 billion, up 32.5% year over year and above the $1.06 billion forecast. The company also declared a quarterly dividend of $0.375, equivalent to a $1.50 annual payout and an approximately 2.6% yield. Neutral Sentiment: Analyst sentiment remains broadly constructive but not decisive. Matador has a consensus “Moderate Buy” rating and an average price target of $66.07, while individual views range from Stephens’ $93 overweight target to Morgan Stanley’s $66 equal-weight target and Truist’s $59 buy target. Negative Sentiment: Zacks Research lowered estimates for Q3 2026 EPS to $0.99 from $1.44, Q4 2026 EPS to $1.26 from $1.41, FY2027 EPS to $6.87 from $7.33, and FY2028 EPS to $7.32 from $7.45. It also reduced Q2 and Q3 2027 forecasts, although it raised its Q4 2027 and Q1 2028 estimates modestly. The revisions suggest continuing uncertainty around Matador’s future earnings, likely related to commodity prices and operating conditions in the Permian Basin. Matador Resources Price Performance MTDR opened at $58.51 on Monday. The company has a fifty day moving average price of $51.46 and a two-hundred day moving average price of $54.51. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.62 and a current ratio of 0.65. Matador Resources Company has a 52 week low of $37.14 and a 52 week high of $66.84. The firm has a market capitalization of $7.24 billion, a PE ratio of 10.04 and a beta of 0.76.

Matador Resources (NYSE:MTDR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The energy company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.08 by $0.53. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Matador Resources had a net margin of 19.85% and a return on equity of 13.18%. The business’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.53 EPS. As a group, analysts anticipate that Matador Resources Company will post 7.26 earnings per share for the current year.

Matador Resources Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Monday, August 10th will be issued a $0.375 dividend. This represents a $1.50 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, August 10th. Matador Resources’s dividend payout ratio is currently 25.73%.

Insider Buying and Selling In related news, EVP William Thomas Elsener bought 850 shares of Matador Resources stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $50.94 per share, for a total transaction of $43,299.00. Following the completion of the acquisition, the executive vice president owned 114,879 shares in the company, valued at approximately $5,851,936.26. This represents a 0.75% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Glenn W. Stetson bought 500 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were bought at an average price of $53.41 per share, with a total value of $26,705.00. Following the completion of the transaction, the chief operating officer directly owned 95,470 shares in the company, valued at approximately $5,099,052.70. This trade represents a 0.53% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 31,996 shares of company stock worth $1,675,663. Company insiders own 5.90% of the company’s stock.

Matador Resources Profile (Free Report)

Matador Resources Company is an independent energy firm primarily engaged in the exploration, development and production of oil, natural gas liquids (NGLs) and natural gas. The company focuses on upstream operations, utilizing horizontal drilling and hydraulic fracturing techniques to unlock hydrocarbons from key reservoirs. Its asset base includes both operated and non‐operated positions, with a particular emphasis on the Permian Basin, one of the most prolific oil-producing regions in North America.

Matador’s core operations are concentrated in the Delaware Basin segment of the Permian Basin, where it holds substantial acreage in both Reeves and Culberson counties in West Texas and Eddy and Lea counties in New Mexico.

Featured Articles Five stocks we like better than Matador Resources VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Matador Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matador Resources and related companies with MarketBeat.com's FREE daily email newsletter.

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders.

LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.

With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851.

“This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement."

The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.

About LX9851
LX9851, discovered by Lexicon and in development by Novo Nordisk, is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5)​. ACSL5 plays a key role in the metabolic pathway which regulates fat accumulation and energy balance. Preclinical in vivo efficacy data presented at Obesity Week 2024 show that LX9851, when combined with semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone. Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation in the preclinical studies.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement   
This press release contains “forward-looking statements,” including statements relating to the preclinical and clinical development of LX9851, Lexicon’s financial position and long-term outlook on its business, growth and future operating results, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.  

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]

BlackRock Inc. bought a new position in FactSet Research Systems Inc. (NYSE:FDS – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 2,858,389 shares of the business services provider’s stock, valued at approximately $657,658,000. BlackRock Inc. owned about 8.04% of FactSet Research Systems as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in FDS. BOKF NA grew its position in FactSet Research Systems by 5,100.0% in the third quarter. BOKF NA now owns 104 shares of the business services provider’s stock worth $30,000 after acquiring an additional 102 shares in the last quarter. Navalign LLC purchased a new stake in FactSet Research Systems during the fourth quarter valued at approximately $32,000. Litman Gregory Wealth Management LLC bought a new stake in shares of FactSet Research Systems in the 4th quarter valued at approximately $32,000. Elyxium Wealth LLC bought a new stake in shares of FactSet Research Systems in the 4th quarter valued at approximately $35,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of FactSet Research Systems by 188.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 98 shares of the business services provider’s stock worth $45,000 after purchasing an additional 64 shares during the period. 91.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their target price on FactSet Research Systems from $275.00 to $280.00 and gave the company a “hold” rating in a research report on Thursday, July 2nd. Barclays raised their price target on FactSet Research Systems from $210.00 to $216.00 and gave the stock an “underweight” rating in a research report on Monday, July 6th. UBS Group reaffirmed a “buy” rating on shares of FactSet Research Systems in a research note on Wednesday, July 22nd. Wells Fargo & Company increased their target price on shares of FactSet Research Systems from $200.00 to $210.00 and gave the company an “underweight” rating in a research note on Thursday, July 2nd. Finally, Jefferies Financial Group raised their target price on shares of FactSet Research Systems from $225.00 to $253.00 and gave the stock a “hold” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, ten have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $253.00.

Read Our Latest Analysis on FDS FactSet Research Systems Stock Down 0.2% Shares of NYSE FDS opened at $299.26 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.68 and a current ratio of 0.68. The firm has a market capitalization of $10.64 billion, a price-to-earnings ratio of 19.71, a PEG ratio of 2.01 and a beta of 0.70. The stock has a 50 day moving average price of $257.01 and a 200 day moving average price of $233.33. FactSet Research Systems Inc. has a 52-week low of $185.00 and a 52-week high of $386.52.

FactSet Research Systems (NYSE:FDS – Get Free Report) last released its quarterly earnings data on Wednesday, July 1st. The business services provider reported $4.53 EPS for the quarter, topping the consensus estimate of $4.44 by $0.09. The company had revenue of $622.92 million for the quarter, compared to the consensus estimate of $617.91 million. FactSet Research Systems had a return on equity of 30.68% and a net margin of 23.21%.FactSet Research Systems’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the business posted $4.27 EPS. FactSet Research Systems has set its FY 2026 guidance at 17.250-17.750 EPS. Sell-side analysts expect that FactSet Research Systems Inc. will post 17.76 earnings per share for the current year.

FactSet Research Systems Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Thursday, September 17th. Stockholders of record on Monday, August 31st will be paid a dividend of $1.16 per share. The ex-dividend date is Monday, August 31st. This represents a $4.64 annualized dividend and a dividend yield of 1.6%. FactSet Research Systems’s dividend payout ratio (DPR) is currently 30.57%.

FactSet Research Systems Company Profile (Free Report)

FactSet Research Systems Inc operates as a global provider of integrated financial data and analytics to the investment community. Founded in 1978 and headquartered in Norwalk, Connecticut, the company offers a unified platform that aggregates content from thousands of sources, delivering real-time and historical market data, company fundamentals, estimates, fixed-income information and proprietary analytics to portfolio managers, research analysts, investment bankers and risk officers.

The company’s core products include the FactSet Workstation, an application offering customizable screening, charting, portfolio analysis and news; APIs and data feeds for seamless integration into proprietary systems; and cloud-based solutions for thematic research and quantitative strategies.

Read More Five stocks we like better than FactSet Research Systems VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding FDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FactSet Research Systems Inc. (NYSE:FDS – Free Report).

Receive News & Ratings for FactSet Research Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FactSet Research Systems and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Jack Henry & Associates, Inc. (NASDAQ: JKHY) today announced its Board of Directors maintained its quarterly cash dividend of $.61 per share. The cash dividend on its common stock, par value $.01 per share, is payable on September 23, 2026, to stockholders of record as of September 7, 2026. Jack Henry has paid consecutive quarterly dividends since 1991, and 2025 marked the 22nd consecutive year of an increasing dividend.

About Jack Henry & Associates, Inc.®
Jack Henry® (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower more than 7,200 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at jackhenry.com.

Statements made in this news release that are not historical facts are "forward-looking statements." Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company's Securities and Exchange Commission filings, including the Company's most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors." Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.

SOURCE Jack Henry & Associates, Inc.

SpaceX (NASDAQ:SPCX | SPCX Price Prediction) stock is down 3% to $133.48 in early Monday trading, extending a slide that has surprised bulls counting on federal launch policy to lift the group. The pullback comes even as President Trump signed a memo directing agencies to target at least 1,000 launches and re-entries annually by 2030.

Also trading lower, Rocket Lab (NASDAQ:RKLB) stock is off 2% to $71.22, and AST SpaceMobile (NASDAQ:ASTS) stock is down 3% to $66.85. Rocket Lab stock was up 75% over the past year through Friday’s close, so a modest cooldown fits a stretched tape running into a critical hardware milestone.

Notably, the selling looks concentrated in the pure-play names. The Procure Space ETF (NASDAQ:UFO) is down just 0.4% to $45.75, a small move that shows broader satellite, defense, and connectivity components are holding the sector together while launch equities take the hit.

Trump’s Launch Memo Meets a Sell-the-News Tape President Donald Trump signed a memo Thursday directing federal agencies to target at least 1,000 launches and re-entries annually by 2030, per Reuters. Last year’s total was 178 launches, framing the order as a dramatic scale-up rather than an incremental push. The memo directs agencies to identify federal land for new launch and re-entry sites, name a new federal re-entry site within 90 days, expedite permitting, speed environmental reviews, and secure wireless spectrum.

White House Office of Science and Technology Policy Director Michael Kratsios called it a commercial-first approach. The angle bulls expected was a straight-line bid for launch and satellite equities. However, the market is pricing execution schedule over demand, and the 2030 target sits well beyond the near-term catalysts investors care about today.

Neutron Timing Is the Real Story for Rocket Lab Rocket Lab CFO Adam Spice said a successful Neutron test launch would flip the company meaningfully adjusted EBITDA positive the following quarter, stating “The path to positive EBITDA is very clear. It’s really getting that first Neutron launch off.” CEO Peter Beck cautioned that “the window for an end-of-year launch is narrowing,” with Neutron still targeted for fourth-quarter pad delivery.

Rocket Lab stock fell for a fourth consecutive session Friday, and Stocktwits retail sentiment flipped to bearish from bullish a week earlier. Meanwhile, Rocket Lab completed Electron’s 93rd flight last week, was selected by Viasat for its Lightning-GEO anti-jam Space Force communications satellite, and joined the $981 million-ceiling NITE-STAR program. None of that changes the calendar risk on Neutron, which is the event investors are actually trading around.

Peers Slip While the Sector ETF Holds Its Ground Intuitive Machines (NASDAQ:LUNR) stock is down 2% to $17.93, cooling after a strong August run tied to lunar contract wins. At the same time, Planet Labs (NYSE:PL) stock is off 2% to $21.94 despite recent momentum in its Earth-imaging business.

Virgin Galactic (NYSE:SPCE) stock is down 0.7% to $3.05, a smaller move that reflects its minimal exposure to the launch cadence trade after the company delayed its first commercial spaceflight to February 2027. SpaceX itself completed two Starlink missions over the weekend, including a Falcon 9 from Vandenberg Space Force Base carrying 27 Starlink satellites, and is preparing its 14th Starship test. SpaceX carried out 170 launches in 2025, illustrating how large the gap is between current industry throughput and the new 1,000-launch target.

What Investors Should Watch Next The setup is a policy tailwind that doesn’t take effect for years running into a hardware schedule that matters this quarter. Investors should consider keeping their position sizes modest in the pure-play launch names until Neutron’s test window firms up, since a slip into 2027 would delay Rocket Lab’s cash-flow inflection and pressure a stock trading at 60.33 times sales.

Investors can watch for Neutron pad-delivery confirmation from Rocket Lab and any near-term federal re-entry site designation, both of which would put real dates behind the launch memo. Traders may want to keep an eye on whether SpaceX stock reclaims its recent range or continues to unwind post-IPO enthusiasm as retail sentiment cools across the launch complex.

Contact [email protected] for any questions or corrections.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Applied Optoelectronics (NASDAQ:AAOI) stock is down 12% to $109.94 early Monday after the company disclosed a plan to raise $600 million through an at-the-market equity offering. The move takes back a slice of what had been a scorching run for the AI optical transceiver name. Applied Optoelectronics stock was up 258% year to date through Friday’s close.

The dilution risk is bleeding into peers. Meanwhile, Lumentum Holdings (NASDAQ:LITE | LITE Price Prediction) stock is down 5% to $822.69, with the shares still up 135% year to date through Friday’s close. Coherent (NYSE:COHR) stock is also down 5% to $273.68, extending a rough stretch for the optics complex. Additionally, Corning (NYSE:GLW) stock is down 3% to $145.90, a shallower cut that lines up with its lighter merchant transceiver exposure.

The selling is concentrated inside optics. The iShares Semiconductor ETF (NASDAQ:SOXX) is down 2% to $511.95. At the same time, the Invesco QQQ Trust (NASDAQ:QQQ) is down 0.6% to $709.22. That spread places the pain squarely in the optical corner of tech rather than across broad semiconductors or mega-cap growth (we profiled seven suppliers powering the AI data-center buildout, from optics to cooling, in a free report here).

$600M ATM Offering Sparks the Selloff Applied Optoelectronics submitted a regulatory filing after Friday’s close outlining the raise. According to Stocktwits, shares are to be sold through Raymond James and Needham, with proceeds earmarked largely for general corporate purposes including debt repayment, working capital and capital expenditures. Retail sentiment on Stocktwits shifted from neutral early Friday to bearish by Sunday, which tracks with the drop this morning.

Context matters here. On the Q2 2026 call, Applied Optoelectronics management said it had already raised $538.8 million net of commissions and fees under an earlier ATM program and made $565.5 million in capital investments during Q2, including $280 million in prepayments on equipment on order. CEO Thompson Lin said “forecast demand continues to outpace our production capacity through mid-2027,” so the incoming cash is targeted at 800G and 1.6 terabit capacity expansion.

The raw math is also digestible. Applied Optoelectronics carries a market cap of roughly $10.55 billion, with 84.57 million shares outstanding, so a $600 million shelf is meaningful without being existential for a name that has more than tripled this year.

Peers Are Reacting, Not Deteriorating Both Lumentum and Coherent beat expectations with upbeat outlooks last week, per Stocktwits. Applied Optoelectronics itself posted record Q2 2026 revenue of $191.92 million, up 86.4% year over year, with adjusted EPS of $0.06 topping the $0.015 consensus. In other words, today’s move at Applied Optoelectronics is a capital-structure event, and the peer selling is a sympathy reaction rather than a fundamental reset.

Lumentum stock and Coherent stock had both been extended heading in. Lumentum shares climbed 638% over the past year, and Coherent shares gained 234% over the same span. When a leader in the same sub-sector announces dilution, momentum-heavy positioning tends to unwind quickly, which is what today looks like across both names.

Corning’s smaller decline underscores the read. Corning stock has run 72% year to date on optical fiber and glass exposure, yet it sits further from merchant transceiver pricing than the pure-play trio. A dilution scare at Applied Optoelectronics simply doesn’t reshape Corning’s optical story to the same degree.

What Investors Should Watch Into the Close Investors sizing their exposure around the optics complex can weigh the sector’s beta profile. Applied Optoelectronics stock has a beta of 3.787 and a 52-week range of $18.50 to $233.67. Position sizes should stay modest relative to a diversified book, because moves like today’s 12% drop are baseline volatility for this name.

Traders can watch for whether Lumentum stock and Coherent stock stabilize once the Applied Optoelectronics shelf is digested, since neither peer has announced its own raise and both carry Q1 FY2027 guidance already on the tape. The Wall Street setup remains constructive, with a $1,148.30 analyst price target on Lumentum stock and a $416.09 target on Coherent stock heading into the session.

Shareholders can stay tuned for follow-on analyst notes on Applied Optoelectronics and any color from management on the pace of ATM issuance. The $163.40 average analyst price target on Applied Optoelectronics stock still sits well above today’s print, so a firm hand on the offering cadence could reset sentiment quickly.

Contact [email protected] for any questions or corrections.

Semtech Corporation (NASDAQ:SMTC) will release its second quarter earnings report after the closing bell on Tuesday, Aug. 25.

Analysts expect the Camarillo, California-based company to report quarterly earnings of 61 cents per share, up from 41 cents per share in the year-ago period. The consensus estimate for Semtech’s quarterly revenue is $328.64 million. It reported $257.6 million last year, according to Benzinga Pro.

On Aug. 13, Semtech agreed to sell its cellular module business to Compal Electronics for $62 million in cash.

Shares of Semtech fell 0.6% to close at $124.09 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

BMO Capital analyst Harsh Kumar initiated coverage on the stock with an Outperform rating and a price target of $155 on Aug. 21, 2026. This analyst has an accuracy rate of 86%. Needham analyst N. Quinn Bolton maintained a Buy with a price target of $200 on Aug. 14, 2026. This analyst has an accuracy rate of 81%. TD Cowen analyst Sean O’Loughlin maintained a Buy rating and raised the price target from $210 to $215 on June 22, 2026. This analyst has an accuracy rate of 72%. UBS analyst Timothy Arcuri maintained a Buy rating and boosted the price target from $165 to $225 on May 27, 2026. This analyst has an accuracy rate of 88%. B. Riley Securities analyst Craig Kennison maintained a Buy rating and raised the price target from $165 to $210 on May 27, 2026. This analyst has an accuracy rate of 58%. Trending

Get a 1% Match on Your First Deposit of $1,000+

Considering buying SMTC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Bank of New York Mellon Corp acquired a new stake in shares of CoreWeave Inc. (NASDAQ:CRWV – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,285,270 shares of the company’s stock, valued at approximately $127,936,000. Bank of New York Mellon Corp owned about 0.29% of CoreWeave as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of CoreWeave by 275.6% in the fourth quarter. Vanguard Group Inc. now owns 27,920,979 shares of the company’s stock worth $1,999,421,000 after buying an additional 20,487,478 shares during the last quarter. Proficio Capital Partners LLC raised its holdings in CoreWeave by 446,194.0% in the 3rd quarter. Proficio Capital Partners LLC now owns 17,851,760 shares of the company’s stock worth $2,443,013,000 after acquiring an additional 17,847,760 shares during the period. Deutsche Bank AG lifted its position in CoreWeave by 22,624.0% during the 4th quarter. Deutsche Bank AG now owns 3,812,856 shares of the company’s stock worth $273,039,000 after acquiring an additional 3,796,077 shares during the last quarter. Altimeter Capital Management LP acquired a new position in CoreWeave during the 4th quarter worth $230,099,000. Finally, Alyeska Investment Group L.P. lifted its position in CoreWeave by 300.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 4,000,000 shares of the company’s stock worth $286,440,000 after acquiring an additional 3,000,000 shares during the last quarter.

Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on CRWV shares. Cantor Fitzgerald set a $176.00 price target on CoreWeave and gave the company an “overweight” rating in a research report on Wednesday, August 12th. UBS Group reissued an “underperform” rating on shares of CoreWeave in a research report on Wednesday, August 12th. Needham & Company LLC restated a “hold” rating on shares of CoreWeave in a research note on Thursday, August 13th. BNP Paribas Exane assumed coverage on CoreWeave in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $192.00 target price on the stock. Finally, Roth Capital set a $145.00 price target on CoreWeave in a research report on Thursday, August 13th. Twenty-one analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $141.57.

Read Our Latest Research Report on CoreWeave Insider Buying and Selling at CoreWeave In other CoreWeave news, COO Sachin Jain sold 6,339 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $91.88, for a total value of $582,427.32. Following the completion of the sale, the chief operating officer owned 157,091 shares in the company, valued at approximately $14,433,521.08. This trade represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian M. Venturo sold 5,899 shares of CoreWeave stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $91.88, for a total value of $542,000.12. Following the sale, the insider directly owned 241,371 shares in the company, valued at $22,177,167.48. The trade was a 2.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 9,541,014 shares of company stock valued at $942,884,194 over the last quarter. Company insiders own 24.20% of the company’s stock.

CoreWeave News Summary Here are the key news stories impacting CoreWeave this week:

Positive Sentiment: CoreWeave announced a multiyear agreement with Hudson River Trading (HRT) to provide AI infrastructure for trading research and model development. The deal reportedly could be worth billions and will use NVIDIA’s next-generation Vera Rubin NVL72 platform and Spectrum-X networking, expanding CoreWeave’s exposure to financial-services customers and supporting demand visibility. Hudson River Trading agreement Positive Sentiment: Analysts continue to point to CoreWeave’s powerful growth: recent quarterly revenue rose 112.5% year over year to $2.58 billion, while its backlog reached more than $104 billion. A bullish research view cited improving margins, operating leverage and strong AI demand, although it acknowledged capital-intensity risks. CoreWeave growth and valuation analysis Neutral Sentiment: Short seller Martin Shkreli reportedly covered his CoreWeave position after holding it for roughly a week. The move removes one source of short-selling pressure but is not necessarily a bullish signal, particularly as the stock continued to face broader volatility. Martin Shkreli covers CoreWeave short Negative Sentiment: CEO Michael Intrator sold 307,692 shares for approximately $29.5 million at an average price of $95.72. The sales were made under a pre-arranged Rule 10b5-1 plan, and he still owns a significant stake, but the size of the transaction weighed on sentiment and raised concerns about insider selling. CoreWeave CEO share sale Negative Sentiment: Bearish commentary argues that CoreWeave’s highly leveraged business model could struggle if AI infrastructure spending slows, capacity becomes excessive or interest rates remain elevated. With a debt-to-equity ratio above 5 and negative earnings, investors remain sensitive to funding costs, dilution risk and the company’s path to profitability. CoreWeave leverage and market risks Negative Sentiment: Northland Securities’ estimates show continued losses through 2027, including projected fiscal 2026 EPS of negative $5.50 and fiscal 2027 EPS of negative $3.18, although the firm expects a return to quarterly profitability in the fourth quarter of 2027. CoreWeave analyst estimates CoreWeave Stock Performance NASDAQ CRWV opened at $87.85 on Monday. The company has a debt-to-equity ratio of 5.53, a current ratio of 0.46 and a quick ratio of 0.46. The firm has a market capitalization of $40.31 billion, a price-to-earnings ratio of -24.07 and a beta of 7.45. The company’s fifty day moving average is $89.99 and its two-hundred day moving average is $94.79. CoreWeave Inc. has a 52-week low of $60.55 and a 52-week high of $153.20.

CoreWeave (NASDAQ:CRWV – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.52) by $0.38. The business had revenue of $2.58 billion during the quarter. CoreWeave had a negative net margin of 25.41% and a negative return on equity of 47.95%. The firm’s quarterly revenue was up 112.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.27) EPS. Equities research analysts forecast that CoreWeave Inc. will post -5.17 EPS for the current year.

CoreWeave Company Profile (Free Report)

CoreWeave is a U.S.-based provider of GPU-accelerated cloud infrastructure designed to support compute-intensive workloads such as artificial intelligence, machine learning, visual effects rendering and other high-performance computing applications. The company supplies access to large fleets of modern GPUs and complementary infrastructure that enable customers to train and deploy large models, run inference at scale, and process graphics-heavy workloads with low latency and high throughput.

CoreWeave’s product offering includes on-demand and dedicated GPU instances, bare-metal servers, private clusters and managed services tailored for enterprise and developer use.

Recommended Stories Five stocks we like better than CoreWeave VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding CRWV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CoreWeave Inc. (NASDAQ:CRWV – Free Report).

Receive News & Ratings for CoreWeave Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoreWeave and related companies with MarketBeat.com's FREE daily email newsletter.

Equinor (EQNR.OL), Aker BP (AKRBP.OL) and Vaar Energi (VAR.OL) are teaming up to drill wells in less explored areas of Norway's continental shelf, aiming to make major ​new oil and gas discoveries after years of smaller finds, they said on ​Monday.

Drilling in areas that have seen little or no prior exploration activity ⁠is more expensive than in mature regions and is associated with greater risk of drilling ​dry holes, but could also yield bigger finds.

"By joining forces we are improving the exploration ​portfolio and we are also reducing the risk," Kjetil Hove, Equinor's head of Norwegian operations, told a joint press conference.

The three companies have agreed to combine expertise, data, technology and exploration capacity to pursue selected ​high impact exploration opportunities, they said.

Much of Norway's drilling in recent years concentrated on finding ​reserves around existing oil and gas fields, yielding a number of smaller discoveries that were quickly brought ‌into ⁠production.

"Near-field exploration remains crucial, but we also need to pursue bigger opportunities to sustain activity and value creation beyond 2035," Hove said.

Norway's output is set to sharply decline during the next decade unless significant new finds are made, government forecasts show.

Over the next four to five ​years, the three companies ​plan to mature ⁠and test a portfolio of approximately 20 to 25 exploration opportunities, with an ambition to drill around five high-impact wells annually.

Starting in 2028, ​the combined annual drilling cost is estimated at around $750 million, divided ​equally between ⁠the three, they said.

Most of the initial drilling would take place at Haltenbanken in the Norwegian Sea, but could extend to all parts of Norway's continental shelf, Hove told Reuters.

Norway, Europe's largest ⁠oil ​and gas producer, encourages energy firms to drill for more ​reserves, hoping to extend the life of its petroleum industry for decades to come despite concerns from environmental groups ​over the climate impact.

, /PRNewswire/ -- Paramount Skydance Corporation (NASDAQ: PSKY) ("Paramount") today announced the extension of the Expiration Dates in connection with the previously announced (i) offers to purchase (the "Tender Offers" and each, a "Tender Offer") for cash, upon the terms and subject to the conditions set forth in the related offer to purchase (the "Offer to Purchase"), any and all of the identified notes in each series of the Existing Tender Offer Notes (defined by reference to the table set forth below) issued by Discovery Global Holdings, Inc. (formerly WarnerMedia Holdings, Inc.) (the "DGH Issuer") and Discovery Communications, LLC (the "DCL Issuer" and together with the DGH Issuer, each a "WBD Issuer" and collectively the "WBD Issuers"), as applicable, and (ii) offers to exchange (the "Exchange Offers" and each, an "Exchange Offer" and, together with the Tender Offers, the "Offers" and each, an "Offer"), upon the terms and subject to the conditions set forth in the related exchange offer memorandum (the "Offering Memorandum"), any and all of the identified notes in each series of the Existing Exchange Offer Notes (defined by reference to the table set forth below) (together with the Existing Tender Offer Notes, the "Offer Notes") issued by the applicable WBD Issuer for notes to be newly issued by Paramount.

The Expiration Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) have been extended to 5:00 p.m., New York City time, on September 4, 2026, unless further extended. The Settlement Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) will occur promptly after the Expiration Date and are currently anticipated to occur in the third quarter of 2026. Paramount anticipates extending the Expiration Date for such Tender Offers and Exchange Offers until such time that would result in the Settlement Dates occurring on or promptly following the closing date of the proposed acquisition (the "Acquisition") by Paramount of Warner Bros. Discovery, Inc. ("WBD"). Tenders of the Offer Notes in the Offers may be withdrawn at any time prior to the Expiration Date. The aforementioned extensions further extend the Expiration Dates previously extended by Paramount on June 12, 2026, June 26, 2026, July 13, 2026, July 17, 2026, July 24, 2026, July 31, 2026, August 7, 2026, and August 17, 2026.

As of 5:00 p.m., New York City time, on August 21, 2026, approximately 64.26% and 73.82% of the aggregate principal amount of the Existing Tender Offer Notes and Existing Exchange Offer Notes, respectively, have been validly tendered in the applicable Offers. As Paramount previously announced that it anticipates extending the Offers to align with the closing date of the Acquisition, Paramount does not view these figures to be representative of the final results of the applicable Offers.

Information about each series of Offer Notes eligible to participate in the Offers is summarized below.

Type of Offer

Offer Notes to be Tendered
or Exchanged, as
Applicable

Issuer of Offer Notes

CUSIP No. / Common Code
/ ISIN Eligible to
Participate in the Offers (1)

Aggregate Principal
Amount of Offer Notes
Eligible to Participate in the
Offers (2)

Tender Offer

3.950% Senior Notes due
2028

DCL Issuer

25470D CP2

US25470DCP24

$1,234,458,000

Exchange Offer

4.125% Senior Notes due
2029

DCL Issuer

25470D CQ0

US25470DCQ07

$655,825,000

Exchange Offer

3.625% Senior Notes due
2030

DCL Issuer

25470D CR8

US25470DCR89

$914,183,000

Exchange Offer

5.000% Senior Notes due
2037

DCL Issuer

25470D CS6

US25470DCS62

$453,281,000

Exchange Offer

6.350% Senior Notes due
2040

DCL Issuer

25470D CT4

US25470DCT46

$438,102,000

Exchange Offer

4.950% Senior Notes due
2042

DCL Issuer

25470D CU1

US25470DCU19

$130,366,000

Exchange Offer

4.875% Senior Notes due
2043

DCL Issuer

25470D V91
CV9US25470DC

$141,584,000

Exchange Offer

5.200% Senior Notes due
2047

DCL Issuer

25470D W74
CW7US25470DC

$3,161,000

Exchange Offer

5.300% Senior Notes due
2049

DCL Issuer

25470D X57
CX5US25470DC

$247,860,000

Tender Offer

3.755% Senior Notes due
2027

DGH Issuer

254948 AH5

US254948AH58

254948 AN2

US254948AN27

U25483 AA3

USU25483AA38

$1,189,336,000

Exchange Offer

4.054% Senior Notes due
2029

DGH Issuer

254948 AJ1

US254948AJ15

254948 AP7

US254948AP74

U25483 AB1

USU25483AB11

$1,353,828,000

Exchange Offer

4.279% Senior Notes due
2032

DGH Issuer

254948 AK8

US254948AK87

254948 AQ5

US254948AQ57

$2,691,764,000

Exchange Offer

5.050% Senior Notes due
2042

DGH Issuer

254948 AL6

US254948AL60

254948 AR3

US254948AR31

U25483 AD7

USU25483AD76

$4,104,687,000

Exchange Offer

5.141% Senior Notes due
2052

DGH Issuer

254948 AM4

US254948AM44

254948 AS1

US254948AS14

$949,883,000

Exchange Offer

4.302% Senior Notes due
2030

DGH Issuer

XS3393993285

339399328

€234,382,000

Exchange Offer

4.693% Senior Notes due
2033

DGH Issuer

XS3393994507

339399450

€316,641,000

__________

(1)

No representation is made as to the correctness or accuracy of the identifiers listed in this press release or printed on the Offer Notes. Such identifiers are provided solely for the convenience of the holders.

(2)

Represents the aggregate principal amount of Offer Notes outstanding that are eligible to participate in the Offers.

The Exchange Offers are being made pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations of the Securities and Exchange Commission (the "SEC") promulgated thereunder, and are also not being registered under any state or foreign securities laws. Any securities offered pursuant to the Exchange Offers may not be offered or sold in the United States or to any U.S. persons (as defined below) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Exchange Offers will only be made, and the securities offered pursuant to the Exchange Offers are only being offered and issued, to holders of applicable Existing Exchange Offer Notes who are (a) reasonably believed to be "qualified institutional buyers" as defined in Rule 144A under the Securities Act or (b) not "U.S. persons," as defined in Rule 902 of Regulation S under the Securities Act (such holders, "Eligible Holders"), and only Eligible Holders who have completed and returned the eligibility certification are authorized to receive or review the Offering Memorandum or to participate in the Exchange Offers. The eligibility certification is available electronically at: https://gbsc-usa.com/eligibility/paramount.

GeneralEach Offer is a separate offer, and each may be individually consummated, amended, extended, terminated, or withdrawn, subject to certain conditions and applicable law, at any time in Paramount's sole discretion, and without also consummating, amending, extending, terminating, or withdrawing any other Offer with respect to any other series of Offer Notes. Paramount may terminate an Offer if any of the conditions of such Offer described in the Offer to Purchase or Offering Memorandum, as applicable, are not satisfied or waived by the applicable Expiration Date, subject to applicable law. In addition, Paramount may waive the conditions to an Offer without extending such Offer in accordance with applicable law.

The Offers are being made solely by Paramount and are not being made by WBD or the WBD Issuers. None of Paramount, WBD, the WBD Issuers, the Dealer Managers, the Exchange Agent (as defined below), the Information Agent (as defined below), the trustees under each of the indentures governing the Offer Notes, the trustee or collateral agent under the indenture that will govern the notes to be issued in the Exchange Offers, or any affiliate of any of them makes any recommendation as to whether any holder of Offer Notes should tender or refrain from tendering all or any portion of the principal amount of such holder's Offer Notes for cash or notes to be issued in the Exchange Offers. No one has been authorized by any of them to make such a recommendation. Holders must make their own decision whether to tender Offer Notes in any Offer and, if so, the amount of Offer Notes to tender.

Only Eligible Holders may receive a copy of the Offering Memorandum and participate in the Exchange Offers. Paramount has engaged Global Bondholder Services Corporation to act as the exchange agent (in such capacity, the "Exchange Agent") and information agent (in such capacity, the "Information Agent") for the Offers. Questions concerning the Offers, or requests for additional copies of the Offer to Purchase or Offering Memorandum or other related documents, may be directed to Corporate Actions by telephone at (855) 654-2014 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or by email at [email protected]. Holders should also consult their broker, dealer, commercial bank, trust company or other institution for assistance concerning the Offers. The Exchange Offer documents and the Tender Offer documents can be accessed at the following link: https://gbsc-usa.com/paramount.

Paramount has engaged BofA Securities and Citigroup as dealer managers (in such capacity, the "Dealer Managers") for the Offers. Holders with questions regarding the Offers should contact BofA Securities, Inc. at +1 (888) 292-0070 (toll-free) or +1 (980) 388-3646 (collect) or [email protected] or Citigroup Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 or [email protected]. Latham & Watkins LLP is serving as legal counsel to Paramount and Cahill Gordon & Reindel LLP is serving as legal counsel to the Dealer Managers.

This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security, and does not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

About Paramount, a Skydance CorporationParamount, a Skydance Corporation is a next-generation global media and entertainment company, comprised of three business segments: Studios, Direct-to-Consumer, and TV Media. PSKY's portfolio unites legendary brands, including Paramount Pictures, Paramount Television, CBS, CBS News, CBS Sports, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount+, Pluto TV, and Skydance Animation, Film, Television, Interactive/Games, and Paramount Sports Entertainment.

PSKY-IR

Cautionary Note Concerning Forward-Looking StatementsThis communication contains "forward-looking statements" regarding the Acquisition and the other transactions referred to herein. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Paramount. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the Acquisition will not be satisfied, including the risk that clearances under applicable antitrust or regulatory laws will not be obtained or will be obtained subject to conditions that are not anticipated; the possibility that the transactions described herein will not be completed in the expected timeframe or at all; the occurrence of any event, change or other circumstances that could give rise to the termination of the Acquisition; potential adverse effects to the businesses of Paramount or WBD during the pendency of the Acquisition, such as employee departures or distraction of management from business operations; negative effects of the announcement or the consummation of the Acquisition on the market price of WBD or Paramount stock; the risk of stockholder litigation relating to the Acquisition, including resulting expense or delay; the potential that the expected benefits and opportunities of the Acquisition, if completed, may not be realized or may take longer to realize than expected; risks related to the streaming business of the post-Acquisition combined business (the "Combined Company"); the adverse impact on the Combined Company's advertising revenues as a result of changes in consumer behavior, advertising market conditions, and deficiencies in audience measurement; risks related to operating in highly competitive and dynamic industries; the unpredictable nature of consumer behavior, as well as evolving technologies and distribution models; risks related to the Combined Company's decision to invest in new businesses, products, services, and technologies, and the evolution of the Combined Company's business strategy; the potential for loss of carriage or other reduction in, or the impact of negotiations for, the distribution of the Combined Company's content; damage to the Combined Company's reputation or brands; losses due to asset impairment charges for goodwill, content and long-lived assets, including finite-lived intangible assets; liabilities related to discontinued operations and former businesses; increasing scrutiny of, and evolving expectations for, sustainability initiatives; evolving business continuity, cybersecurity, privacy and data protection and similar risks; challenges in protecting and maintaining the Combined Company's intellectual property rights; domestic and global political, economic and regulatory factors affecting the Combined Company's business generally or the Acquisition; the inability to hire or retain key employees or secure creative talent; disruptions to the Combined Company's operations as a result of labor disputes; risks and costs associated with the integration of, and Paramount's ability to integrate, the businesses of Paramount Global, Skydance Media, LLC, and WBD successfully and to achieve anticipated synergies, including in the amounts or on the timelines anticipated to realize such synergies; litigation related to the Acquisition and other matters or transactions; risks associated with the Combined Company's holding company structure, including its dependence on distributions from its subsidiaries to meet tax obligations and other cash requirements; risks related to our indebtedness, including our substantial outstanding debt obligations, our ability to incur substantially more debt and our ability to meet the financial and other covenants contained in the agreements governing the indebtedness of Paramount, WBD, or the Combined Company. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Paramount and WBD can be found in Paramount's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 25, 2026, including in the sections captioned "Cautionary Note Concerning Forward-Looking Statements" and "Item 1A. Risk Factors," Paramount's most recently filed Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 4, 2026, including in the sections captioned "Cautionary Note Concerning Forward-Looking Statements" and "Item 1A. Risk Factors," and Paramount's subsequent filings with the SEC, and in WBD's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, including in the section captioned "Item 1A. Risk Factors," WBD's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, and WBD's subsequent filings with the SEC. Neither Paramount nor WBD undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.

SOURCE Paramount Skydance Corporation

Commercial framework identifies NANO Nuclear as Tillman's preferred nuclear technology provider; Parties targeting 2 gigawatts ("GW") or more of advanced nuclear capacity by the mid-2030s and 6 GW or more by 2040

Framework also includes fully milestone-vesting warrants for Tillman to purchase up to $100 million of NANO Nuclear Energy common stock, with a majority of the warrants vesting upon future binding reactor purchase commitments and a portion vesting upon achievement of key project-development milestones

New York, New York--(Newsfile Corp. - August 24, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor and technology company focused on developing next-generation energy solutions, today announced the signing of a non-binding Strategic Commercial Framework with Tillman Global Holdings ("TGH" or "Tillman") and its global data-center platform, Tillman Digital Gateway ("TDG"), to advance the future deployment of NANO Nuclear's KRONOS MMR™ Energy Systems across Tillman's planned AI industrial zones in the United States.

The framework identifies NANO Nuclear as Tillman's anticipated preferred nuclear technology provider and establishes a structure for the parties to collaborate on the evaluation and development of nuclear generation opportunities across Tillman's growing U.S. data-center pipeline, with a parallel opportunity to expand to certain international markets.

In connection with the proposed collaboration, the parties are targeting 2 GW or more of advanced nuclear capacity by the mid-2030s and 6 GW or more by 2040, subject to general and site-specific definitive agreements, customer commitments, financing, regulatory approvals and other project requirements.

Tillman, a global firm that develops, owns, and scales large-scale digital and energy infrastructure, is advancing a multi-state pipeline of planned AI industrial zones in the U.S. designed to support gigawatt-scale power requirements from anticipated hyperscale and AI tenant customers. As part of its power-first development strategy, Tillman evaluates sites for their ability to accommodate multiple sources of generation and intends to reserve the space to integrate advanced nuclear power as a medium- to long-term source of reliable, baseload generation.

Figure 1 - NANO Nuclear and Tillman Digital Gateway Sign Strategic Commercial Framework to Advance Nuclear Power for Gigawatt-Scale U.S. AI Industrial Zones

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/311012_76d0c2c274ee3872_003full.jpg

Under the framework, NANO Nuclear and Tillman intend to collaborate across the nuclear project-development lifecycle, including site evaluation and diligence, licensing and development planning, customer engagement and project deployment. The contemplated structure would combine Tillman's infrastructure development, project financing and power-development capabilities with NANO Nuclear's advanced reactor technology, nuclear licensing capabilities and integrated approach to the nuclear fuel cycle.

Combining Complementary Infrastructure and Nuclear Capabilities

Tillman and its affiliated companies have significant experience developing, financing, owning and operating large-scale digital and energy infrastructure, including U.S. cell towers, fiber infrastructure, in-building connectivity systems and electric vehicle charging infrastructure, and have secured approximately $16 billion of capital since inception. Tillman is leveraging this experience for the development of power-first AI infrastructure designed to address the scale, reliability and speed-to-market requirements of next-generation computing customers.

NANO Nuclear is developing its KRONOS MMR Energy System, a 15 MWe High-Temperature Gas-Cooled Reactor designed to support modular and phased deployment. The parties believe the technology's modular architecture is particularly well-suited for staged deployment at large-scale data-center campuses as nuclear generation becomes available over the medium and long term.

"Power availability is becoming one of the defining constraints on the continued expansion of AI infrastructure, and addressing this challenge will require both near-term execution and long-term planning," said James Walker, Chief Executive Officer of NANO Nuclear Energy. "This framework represents a milestone in our future customer acquisition strategy, as Tillman brings deep infrastructure-development capabilities, access to capital and relationships across the technology ecosystem, together with a power-first approach to developing the next generation of AI campuses. By planning for nuclear at the earliest stages of site development, we believe we can establish a practical pathway to introduce reliable, baseload power as these campuses scale."

"For NANO Nuclear, this framework represents an important potential commercialization pathway that connects our technology with an anticipated multi-gigawatt-site pipeline of power demand," said Jay Yu, Founder and Chairman of NANO Nuclear Energy. "Importantly, the structure is intended to align both organizations around measurable project-development and commercial milestones as individual opportunities progress. We believe combining Tillman's infrastructure-development capabilities with our nuclear technology, regulatory licensing pathway and deployment model can create a scalable foundation for future nuclear-powered AI infrastructure."

"Meeting the extraordinary power requirements of next-generation AI infrastructure requires us to plan not only for what our campuses need today, but for the resilient, scalable power architecture they will require for decades to come," said Sachit Ahuja, Co-President of Tillman Global Holdings. "We view NANO Nuclear as an emerging leader in advanced nuclear whose progress to date, commercially focused strategy and modular technology platform make it a compelling potential solution for our medium- and long-term power requirements. This framework combines Tillman's infrastructure-development platform and relationships with large-scale technology customers and NANO Nuclear's advanced nuclear capabilities, creating a pathway to benefit from the integration of nuclear generation into future Tillman campuses as our portfolio expands."

Potential Multi-Gigawatt Deployment Pathway

As part of the proposed collaboration, the parties are targeting 2 GW or more of advanced nuclear capacity by the mid-2030s, with a longer-term objective of 6 GW or more by 2040 across Tillman projects. The parties are also evaluating opportunities to extend their collaboration to select international markets where Tillman or its affiliates are developing or evaluating large-scale digital infrastructure.

Key Elements of the Proposed Framework

Preferred nuclear technology relationship: The framework identifies NANO Nuclear as Tillman's proposed preferred nuclear technology provider for potential advanced nuclear energy deployments across Tillman's planned U.S. AI industrial zones.

Joint project development: Tillman and NANO Nuclear intend to evaluate candidate sites for future nuclear energy deployment and collaborate on site diligence, development and licensing planning, customer engagement and project structuring as individual opportunities advance.

IPP-style deployment model: For qualifying projects, the parties contemplate an independent-power-producer-style structure under which Tillman or its affiliates would finance, develop and own project power infrastructure and NANO Nuclear would develop, support operations, and supply the reactors and fuel, with specific commercial arrangements to be negotiated on a project-by-project basis.

Milestone-Based Warrant Arrangement and $5 Million Initial Equity Grant: The framework contemplates the proposed issuance to Tillman of fully milestone-vesting warrants to purchase up to $100 million of NANO Nuclear common stock. A majority of the warrants would vest only upon future binding reactor purchase commitments. The remaining portion of the warrants would vest only upon achievement of specified project-development milestones.

The framework also contemplates an initial restricted common stock grant to Tillman with a notional value of $5 million, a portion of which would vest upon execution of definitive equity grant agreements, with the substantial majority vesting only upon achievement of specified project-development milestones.

Project-level equity participation: The framework also contemplates potential rights for NANO Nuclear to participate alongside Tillman in a portion of the equity of certain project-level entities associated with future nuclear generation and corresponding data-center development once qualifying nuclear projects reach specified development milestones. Any such participation is subject to separately negotiated project-specific terms and definitive agreements.

All of the foregoing terms remain subject to evolution based on the preparation and execution of definitive documentation.

NANO Nuclear is being advised on the transaction by EAS Advisors LLC, acting through Odeon Capital Group LLC.

About Tillman Global Holdings

Tillman Global Holdings is a U.S.-based holding company that builds and scales leading businesses in essential digital and energy infrastructure. Founded in 2013 by Sanjiv Ahuja, the firm operates with a long-term, operator-led approach, leveraging deep expertise and disciplined capital allocation to address evolving customer and connectivity needs. Tillman applies its hands-on management model to create robust infrastructure platforms that support economic growth and deliver long-term value across the territories in which it operates.

Tillman's current portfolio companies operate premier fiber networks, mobile tower platforms, hyperscale data centers, in-building connectivity systems, and energy infrastructure. For more information, visit tillmanglobal.com.

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, "ZEUS", a portable solid core battery reactor, and the space focused, portable LOKI MMR™, each representing advanced developments in energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:

NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward-Looking Statements

This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "contemplated", "expects", "anticipates", "intends", "explore," "plans", "aim," "goal," "believes", "potential", "will", "should", "could", "would" or "may" or derivations of these words and other words of similar meaning about the future, although these are not the exclusive terms that denote forward-looking statements. In this press release, forward-looking statements include those relating to (i) the Company's potential commercial collaboration with Tillman, which is presently only subject to a non-binding written framework and remains subject to the preparation, negotiation and execution of both general and project specific definitive agreements and (ii) the Company's and Tillman's business and operational development plans in general. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, the risk that the Company and Tillman may never advance beyond the exploratory stage and reach definitive documentation (on the terms set forth herein, or at all) or an actual investment by Tillman in the Company, as well as the following: (i) risks related to our U.S. Department of Energy ("DOE"), U.S. Nuclear Regulatory Commission ("NRC"), Canadian Nuclear Safety Commission ("CNSC") or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311012

Source: NANO Nuclear Energy Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Capstone Wealth Management Group Inc. bought a new stake in shares of Meta Platforms, Inc. (NASDAQ:META – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,317 shares of the social networking company’s stock, valued at approximately $1,869,000. Meta Platforms comprises 1.1% of Capstone Wealth Management Group Inc.’s investment portfolio, making the stock its 19th largest holding.

Other hedge funds have also recently modified their holdings of the company. Ashton Thomas Securities LLC raised its stake in Meta Platforms by 17.4% during the 1st quarter. Ashton Thomas Securities LLC now owns 18,000 shares of the social networking company’s stock valued at $10,299,000 after buying an additional 2,670 shares during the last quarter. Keybank National Association OH lifted its holdings in shares of Meta Platforms by 15.7% during the 4th quarter. Keybank National Association OH now owns 133,798 shares of the social networking company’s stock valued at $88,319,000 after buying an additional 18,169 shares during the period. WMS Group LLC purchased a new position in shares of Meta Platforms in the 4th quarter worth $876,000. Vanguard Group Inc. boosted its stake in shares of Meta Platforms by 3.8% in the 4th quarter. Vanguard Group Inc. now owns 199,995,630 shares of the social networking company’s stock worth $132,015,115,000 after buying an additional 7,269,279 shares during the last quarter. Finally, Czech National Bank grew its holdings in shares of Meta Platforms by 4.9% in the second quarter. Czech National Bank now owns 625,079 shares of the social networking company’s stock worth $352,101,000 after acquiring an additional 29,411 shares during the period. Hedge funds and other institutional investors own 79.91% of the company’s stock.

Analysts Set New Price Targets META has been the subject of a number of research reports. Raymond James Financial upped their price objective on Meta Platforms from $825.00 to $850.00 and gave the company a “strong-buy” rating in a research report on Tuesday, July 21st. Citigroup dropped their target price on Meta Platforms from $850.00 to $800.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. KeyCorp cut their price target on Meta Platforms from $790.00 to $780.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Wedbush reduced their price target on shares of Meta Platforms from $671.00 to $595.00 and set a “neutral” rating for the company in a research report on Thursday, July 30th. Finally, Wells Fargo & Company lowered their price objective on shares of Meta Platforms from $835.00 to $640.00 and set an “overweight” rating on the stock in a research note on Thursday, July 30th. Four analysts have rated the stock with a Strong Buy rating, thirty-five have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Meta Platforms has an average rating of “Moderate Buy” and a consensus price target of $785.32.

Check Out Our Latest Report on Meta Platforms Meta Platforms Price Performance NASDAQ META opened at $549.90 on Monday. The business’s fifty day moving average is $593.51 and its 200 day moving average is $614.77. Meta Platforms, Inc. has a fifty-two week low of $520.26 and a fifty-two week high of $790.80. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.23 and a current ratio of 2.23. The company has a market capitalization of $1.40 trillion, a PE ratio of 20.71, a price-to-earnings-growth ratio of 0.94 and a beta of 1.25.

Meta Platforms (NASDAQ:META – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The social networking company reported $6.18 EPS for the quarter, missing analysts’ consensus estimates of $7.19 by ($1.01). Meta Platforms had a return on equity of 33.18% and a net margin of 29.83%.The company had revenue of $60.80 billion during the quarter, compared to analysts’ expectations of $60.22 billion. During the same quarter in the previous year, the company earned $7.14 EPS. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. Sell-side analysts predict that Meta Platforms, Inc. will post 28.5 earnings per share for the current year.

Meta Platforms Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Monday, June 15th were paid a dividend of $0.525 per share. The ex-dividend date was Monday, June 15th. This represents a $2.10 dividend on an annualized basis and a dividend yield of 0.4%. Meta Platforms’s payout ratio is 7.91%.

Key Meta Platforms News Here are the key news stories impacting Meta Platforms this week:

Positive Sentiment: Meta launched Pocket in the U.S., an AI-powered app that lets users create and share interactive games through text prompts. The product could increase engagement and expand Meta’s consumer AI ecosystem. Meta brings Pocket to U.S. users Positive Sentiment: Meta introduced a Mac app for Meta AI with system-wide dictation and screen-aware assistance. The company is also pricing its new Muse Code coding agent below Anthropic and OpenAI offerings, potentially helping it attract developers and build AI adoption. Meta AI launches Mac app Positive Sentiment: Meta’s core advertising business remains strong, with quarterly revenue rising 28% year over year to $60.8 billion. AI-related improvements to recommendations and ad delivery are supporting engagement, clicks and conversion efficiency. Meta drawdown analysis Neutral Sentiment: Meta is contesting the Federal Trade Commission’s effort to revive monopoly charges. The company argues that Facebook and Instagram users increasingly see recommended content rather than posts from friends, a defense that could influence the case’s regulatory implications. Meta fights FTC monopoly charges Neutral Sentiment: Meta’s CTO Andrew Bosworth, CFO Susan Li and insider Curtis Mahoney sold shares worth roughly $10.3 million in aggregate under pre-arranged Rule 10b5-1 plans. The transactions are limited as discretionary signals but may still affect investor sentiment. Meta insider transaction filing Negative Sentiment: Child-safety and social-media addiction litigation is intensifying. Testimony alleging that some safety tools were “designed to fail” raises the possibility of major damages, mandated product changes, restrictions on engagement features and pressure on advertising monetization. Meta social media lawsuit trial Negative Sentiment: Investors remain concerned that heavier AI capital spending will depress second-half free cash flow and increase financial pressure. Those concerns follow Meta’s quarterly EPS miss, despite its revenue beat, and have contributed to the stock’s year-to-date weakness. Meta stock investment analysis Insider Buying and Selling In other Meta Platforms news, CTO Andrew Bosworth sold 7,848 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $558.00, for a total transaction of $4,379,184.00. Following the sale, the chief technology officer owned 828 shares in the company, valued at approximately $462,024. This trade represents a 90.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Javier Olivan sold 1,258 shares of Meta Platforms stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $600.00, for a total transaction of $754,800.00. Following the transaction, the chief operating officer directly owned 1,517 shares in the company, valued at $910,200. This represents a 45.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 38,502 shares of company stock worth $22,603,485 in the last ninety days. Corporate insiders own 13.53% of the company’s stock.

About Meta Platforms (Free Report)

Meta Platforms, Inc (NASDAQ: META), formerly Facebook, Inc, is a global technology company best known for building social networking services and immersive computing platforms. Founded in 2004 and headquartered in Menlo Park, California, the company operates a family of consumer-facing products and services that connect users, creators and businesses. In October 2021 the company rebranded as Meta to reflect an expanded strategic focus on augmented and virtual reality technologies alongside its social media businesses.

Meta’s core consumer products include Facebook, Instagram, WhatsApp and Messenger, which enable social networking, messaging, content sharing and community building across mobile and desktop devices.

Read More Five stocks we like better than Meta Platforms VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Meta Platforms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meta Platforms and related companies with MarketBeat.com's FREE daily email newsletter.

Amazon (NASDAQ:AMZN | AMZN Price Prediction) shares are trading at $258.63 as of Friday’s close, down 2.47% over the past week but up 14.19% year to date. Still, shares of the hyperscaler sit well below their 52-week high of $287.16, and the Street’s consensus price target sits at $280.47.

Most analysts hold constructive but measured outlooks. TD Cowen, however, is making a significantly bolder call on AWS revenue, centered on one argument: Wall Street is still underestimating Amazon’s AI-driven cloud growth. Can AMZN realistically reach TD Cowen’s implied target by end of 2026?

TD Cowen’s $165 Billion AWS Prediction TD Cowen raised its AWS revenue estimate to $165 billion for 2026, placing it 3% above Wall Street consensus, and extended that view to $222 billion for 2027, which is 11% above consensus. The firm’s thesis rests on generative AI tailwinds and Amazon’s commitment to approximately $200 billion in capital expenditures in 2026, predominantly directed at AI infrastructure. TD Cowen believes the divergence between its estimates and consensus will widen as enterprise AI workloads accelerate through the year.

Key Drivers of AMZN Stock Performance 1. AWS acceleration with room to run: AWS closed Q4 2025 at a $142 billion annualized run rate, growing 24% year-over-year, the fastest pace in 13 quarters. That trajectory directly underpins TD Cowen’s $165 billion estimate. A cloud business compounding at that rate inside a diversified mega-cap offers durable, long-horizon growth without the volatility of pure-play AI names.

2. Custom silicon creating a structural cost advantage: Amazon’s Trainium and Graviton chips now carry a combined annualized revenue run rate well over $10 billion, growing triple-digit percentages year-over-year. Proprietary chips lower inference costs for customers and improve Amazon’s own economics, compounding margins over time.

3. Enterprise AI adoption still in early innings: Over 100,000 companies are using Amazon Bedrock, and CEO Andy Jassy described enterprise production workloads as “the lion’s share of that demand still yet to come.” That pipeline represents multi-year compounding revenue with a 5-to-10-year horizon.

What Will It Take for AMZN to Reach TD Cowen’s Target? With 10.73 billion shares outstanding and a current market cap of approximately $2.2 trillion, meaningful upside requires AWS to sustain its growth trajectory while operating margins expand. Three conditions matter most: AWS must maintain or accelerate its growth rate through 2026 as new AI capacity comes online; the $200 billion CapEx cycle must translate into revenue faster than the market currently models; and enterprise migration from on-premise infrastructure to cloud must continue broadening beyond the AI labs that currently dominate demand.

The primary risk is straightforward: Free cash flow declined 37.12% year-over-year in Q4 2025 as CapEx surged, and sustaining that investment pace without visible near-term return will pressure sentiment. Still, with 63 out of 67 analyst ratings at Buy or Strong Buy and TD Cowen’s AWS estimates sitting materially above consensus through 2027, the institutional conviction behind this growth story remains among the strongest in large-cap tech.

Contact [email protected] for any questions or corrections.

Community Trust & Investment Co. lifted its stake in shares of Microsoft Corporation (NASDAQ:MSFT – Free Report) by 7.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 256,067 shares of the software giant’s stock after buying an additional 17,044 shares during the quarter. Microsoft makes up approximately 4.9% of Community Trust & Investment Co.’s portfolio, making the stock its 4th biggest position. Community Trust & Investment Co.’s holdings in Microsoft were worth $95,518,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MSFT. Vanguard Group Inc. raised its position in shares of Microsoft by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 717,942,580 shares of the software giant’s stock worth $347,211,391,000 after acquiring an additional 15,955,898 shares in the last quarter. State Street Corp boosted its holdings in Microsoft by 2.1% in the fourth quarter. State Street Corp now owns 306,150,608 shares of the software giant’s stock valued at $148,060,557,000 after purchasing an additional 6,388,930 shares in the last quarter. Geode Capital Management LLC increased its stake in Microsoft by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 182,618,400 shares of the software giant’s stock valued at $88,056,019,000 after purchasing an additional 1,911,142 shares during the last quarter. Morgan Stanley increased its stake in Microsoft by 0.8% in the fourth quarter. Morgan Stanley now owns 121,220,561 shares of the software giant’s stock valued at $58,624,690,000 after purchasing an additional 980,439 shares during the last quarter. Finally, Norges Bank acquired a new stake in Microsoft during the fourth quarter worth approximately $50,664,631,000. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets In other Microsoft news, EVP Takeshi Numoto sold 4,810 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $496.48, for a total value of $2,388,068.80. Following the sale, the executive vice president owned 42,677 shares of the company’s stock, valued at approximately $21,188,276.96. This represents a 10.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Judson Althoff sold 10,000 shares of Microsoft stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $487.89, for a total value of $4,878,900.00. Following the transaction, the chief executive officer directly owned 100,447 shares of the company’s stock, valued at $49,007,086.83. This trade represents a 9.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 37,310 shares of company stock worth $17,256,219. 0.03% of the stock is owned by company insiders.

Analyst Ratings Changes A number of equities research analysts recently weighed in on the stock. TD Cowen reissued a “buy” rating and issued a $540.00 price target on shares of Microsoft in a research report on Thursday, July 30th. Scotiabank reiterated an “outperform” rating and set a $510.00 target price on shares of Microsoft in a research report on Thursday, July 30th. Stifel Nicolaus boosted their target price on Microsoft from $400.00 to $450.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Royal Bank Of Canada reissued an “outperform” rating and issued a $640.00 target price on shares of Microsoft in a research report on Thursday, July 30th. Finally, Citigroup restated a “buy” rating and set a $600.00 price target (up from $570.00) on shares of Microsoft in a research note on Tuesday, July 28th. Forty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $560.27. View Our Latest Stock Report on MSFT

Key Microsoft News Here are the key news stories impacting Microsoft this week:

Positive Sentiment: Microsoft is reportedly preparing to launch its Maia 300 AI accelerator as soon as this fall and is discussing production with TSMC. Developing proprietary chips could reduce long-term reliance on Nvidia, improve supply-chain control, and support Microsoft’s expanding AI infrastructure. Microsoft’s Betting Big on Its Own AI Chips Positive Sentiment: Meta has reportedly become one of Microsoft’s largest Azure AI customers, spending hundreds of millions of dollars annually and consuming substantial computing capacity. The relationship reinforces evidence that enterprise demand is translating into Azure revenue. Meta Emerges as a Major Microsoft Azure AI Client Positive Sentiment: Microsoft raised its quarterly dividend to $0.91 per share, while Azure revenue reportedly surpassed $100 billion. Analysts and financial commentators also highlighted a roughly $678 billion backlog and continued strong demand for cloud and AI services. Microsoft Raises Dividend as AI Capital Spending Hits Record Levels Neutral Sentiment: Microsoft approved the Horizon 1 Texas data-center project involving IREN, potentially expanding capacity available for AI workloads. The development is strategically relevant, although the near-term financial benefit to Microsoft remains unclear. Microsoft Accepts Horizon 1 Negative Sentiment: Annual capital spending has climbed nearly 80% to about $115.9 billion, while free cash flow declined. Investors remain focused on whether AI revenue growth will generate adequate returns on this spending. Microsoft Spent $115.9 Billion on AI Negative Sentiment: TCI Management reportedly exited its Microsoft position and increased its Alphabet stake, adding a notable institutional-selling signal. Separately, commentary warned that Microsoft’s valuation depends on optimistic earnings forecasts, while higher bond yields could reduce the present value of future AI profits. TCI Exits Microsoft Microsoft Price Performance Shares of NASDAQ MSFT opened at $483.24 on Monday. The firm has a market capitalization of $3.59 trillion, a P/E ratio of 26.91, a PEG ratio of 1.56 and a beta of 1.10. Microsoft Corporation has a one year low of $349.20 and a one year high of $553.72. The company’s fifty day moving average is $419.61 and its two-hundred day moving average is $409.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.22 and a current ratio of 1.23.

Microsoft (NASDAQ:MSFT – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The software giant reported $4.74 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.50. Microsoft had a net margin of 40.31% and a return on equity of 31.98%. The firm had revenue of $90.01 billion for the quarter, compared to the consensus estimate of $87.62 billion. During the same quarter in the previous year, the firm earned $3.65 earnings per share. The firm’s revenue was up 17.7% on a year-over-year basis. Analysts forecast that Microsoft Corporation will post 19.59 EPS for the current fiscal year.

Microsoft Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Thursday, August 20th will be issued a dividend of $0.91 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $3.64 annualized dividend and a yield of 0.8%. Microsoft’s payout ratio is currently 20.27%.

About Microsoft (Free Report)

Microsoft Corporation is a global technology company headquartered in Redmond, Washington. Founded in 1975 by Bill Gates and Paul Allen, Microsoft develops, licenses and supports a broad range of software products, services and devices for consumers, enterprises and governments worldwide. Its operations span personal computing, productivity software, cloud infrastructure, enterprise applications, developer tools and gaming.

Microsoft’s product portfolio includes the Windows operating system and the Microsoft 365 suite of productivity and collaboration tools (Office apps, Outlook, Teams).

Featured Articles Five stocks we like better than Microsoft VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Microsoft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microsoft and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of Nova Scotia acquired a new stake in shares of The Boeing Company (NYSE:BA – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 221,835 shares of the aircraft producer’s stock, valued at approximately $48,043,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Boeing by 5.1% during the 4th quarter. Vanguard Group Inc. now owns 70,989,438 shares of the aircraft producer’s stock valued at $15,413,227,000 after purchasing an additional 3,460,021 shares during the last quarter. Newport Trust Company LLC lifted its position in Boeing by 1.0% during the fourth quarter. Newport Trust Company LLC now owns 29,485,294 shares of the aircraft producer’s stock valued at $6,401,847,000 after purchasing an additional 286,848 shares in the last quarter. Geode Capital Management LLC grew its holdings in Boeing by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 17,025,435 shares of the aircraft producer’s stock valued at $3,679,592,000 after purchasing an additional 533,753 shares during the period. Fisher Asset Management LLC increased its position in Boeing by 2.5% in the fourth quarter. Fisher Asset Management LLC now owns 5,640,900 shares of the aircraft producer’s stock worth $1,224,752,000 after buying an additional 135,860 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Boeing by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,370,415 shares of the aircraft producer’s stock worth $948,905,000 after buying an additional 138,469 shares in the last quarter. Institutional investors own 64.82% of the company’s stock.

Boeing Price Performance Boeing stock opened at $214.20 on Monday. The Boeing Company has a 52-week low of $176.77 and a 52-week high of $254.35. The company has a quick ratio of 0.33, a current ratio of 1.14 and a debt-to-equity ratio of 6.77. The firm’s fifty day moving average is $222.11 and its 200 day moving average is $222.18. The company has a market cap of $169.30 billion, a price-to-earnings ratio of 92.73 and a beta of 1.21.

Boeing (NYSE:BA – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The aircraft producer reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.42). The company had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.26 billion. Boeing had a negative return on equity of 346.82% and a net margin of 2.41%.The company’s revenue was up 8.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.24) earnings per share. Sell-side analysts forecast that The Boeing Company will post -0.87 EPS for the current fiscal year. Analysts Set New Price Targets BA has been the topic of a number of analyst reports. Sanford C. Bernstein began coverage on Boeing in a research report on Tuesday, August 11th. They set an “outperform” rating on the stock. Barclays lowered shares of Boeing from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, August 11th. Royal Bank Of Canada decreased their price objective on shares of Boeing from $275.00 to $265.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 29th. The Goldman Sachs Group cut shares of Boeing from a “buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Robert W. Baird set a $300.00 target price on shares of Boeing in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Boeing currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.58.

View Our Latest Stock Analysis on Boeing

Key Headlines Impacting Boeing Here are the key news stories impacting Boeing this week:

Positive Sentiment: The U.S. State Department approved a potential $4.5 billion sale of KC-46A tanker aircraft to Qatar. The approval supports Boeing’s defense backlog, although the transaction still requires finalization. US approves potential $4.5B sale of Boeing KC-46A tankers to Qatar Positive Sentiment: Boeing’s agreement to sell or transfer businesses including Wisk Aero, Insitu and SkyGrid to Archer Aviation, while taking a strategic stake in Archer, could generate cash and provide exposure to autonomous and electric aviation markets. However, the deal’s financial impact and execution remain uncertain. Archer Aviation bets big on becoming more than an air taxi company Neutral Sentiment: AerCap delivered its tenth Boeing 787 to Grupo Aeromexico, marking its 100th 787 delivery from its direct order book. The milestone signals continuing customer demand for the Dreamliner but is not a new Boeing order or immediate revenue catalyst. AerCap Holdings compared with Boeing Negative Sentiment: Voting ends on Boeing’s proposed four-year contract with the Society of Professional Engineering Employees in Aerospace, representing roughly 17,000 engineers and technical workers. A rejection could authorize a strike after the current contracts expire on October 6, raising concerns about production, certification and delivery schedules. Results were expected Friday afternoon. Boeing white-collar union contract vote results expected today Negative Sentiment: The labor uncertainty is outweighing recent operating progress, including higher commercial deliveries and efforts to increase 737 production. Investors appear concerned that a work stoppage could interrupt Boeing’s recovery. Boeing slides as labor vote uncertainty outweighs operational progress Negative Sentiment: Boeing is advancing repairs to Air Force One, but window replacement and interior work could threaten the program’s schedule, adding another execution risk to the company’s defense business. Boeing advances Air Force One repairs Boeing Company Profile (Free Report)

Boeing Company (NYSE: BA) is an American multinational corporation that designs, manufactures and services commercial airplanes, defense systems, and space and security technologies. Founded in 1916 by William E. Boeing in Seattle, the company today operates as an integrated aerospace and defense contractor with a global customer base. Boeing relocated its corporate headquarters to Arlington, Virginia in 2022 and maintains extensive engineering, manufacturing and service operations across the United States and around the world.

Boeing’s principal lines of business include Commercial Airplanes, which produces and supports a range of jetliners used by airlines globally; Defense, Space & Security, which develops military aircraft, rotorcraft, surveillance and reconnaissance systems, satellites, and launch and missile systems; and Boeing Global Services, which provides aftermarket maintenance, training, spare parts, digital analytics and logistics support.

Further Reading Five stocks we like better than Boeing VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding BA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Boeing Company (NYSE:BA – Free Report).

Receive News & Ratings for Boeing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boeing and related companies with MarketBeat.com's FREE daily email newsletter.

Nike (NYSE: NKE) investors holding 100 shares will receive $41 when the company pays its next quarterly dividend on October 1, 2026.

The payment was declared on August 6 with no change from the previous quarterly payout of $0.41 per share. 

Investors must own the stock before the September 1, 2026 ex-dividend date to qualify. The payout maintains Nike’s annual dividend rate at $1.64 per share, giving the stock a 4.02% yield at its recent price of $40.76.

If the dividend remains unchanged for a full year, investors holding 100 shares would collect approximately $164 annually.

Nike dividend payment schedule. Source: Dividend.com Notably, Nike’s dividend yield is significantly higher than the 1.89% average yield across the consumer discretionary sector. 

Meanwhile, the company’s forward payout ratio stands at 75.25%, indicating a substantial portion of earnings is being returned to shareholders through dividends.

It is worth noting that Nike last increased its dividend in late 2025, raising the quarterly payment from $0.40 to $0.41 per share. The increase extended the company’s dividend growth streak to roughly 24 consecutive years, bringing it within one year of qualifying for Dividend Aristocrat status.

If Nike announces another increase later this year matching the previous hike of about 2.5%, the quarterly dividend would rise to approximately $0.42025 per share.

Indeed, the company has historically announced its annual dividend increase in November, making a potential hike later in 2026 a key event for income-focused investors.

Nike’s elevated dividend yield comes as the stock remains under heavy pressure. Shares fell to a 12-year low of $38.86 before recovering to $40.76 as of August 21.

Nike stock price struggles  The stock has lost about 48% over the past year, more than 35% year-to-date, and nearly 78% from its November 2021 record high of $177.

NKE YTD stock price chart. Source: Finbold The latest sell-off was largely triggered by disappointing results and weaker guidance from rival On Holding, which weighed on sentiment across the premium athletic footwear sector.

Additional pressure has come from a recent JPMorgan downgrade to ‘Underweight’ with a $40 price target, concerns over weak demand in China, softness in Nike’s direct-to-consumer business, increased competition, tariff-related headwinds, and a slower-than-expected turnaround under CEO Elliott Hill.

Despite these challenges, Nike has maintained its focus on returning capital to investors. The company returned approximately $2.5 billion to shareholders during fiscal 2026, primarily through dividends, while significantly reducing share buybacks as free cash flow remained under pressure.

At the same time, revenue stabilized near $46.4 billion in fiscal 2026, with improvements in North America and wholesale operations helping offset ongoing weakness in China and several other markets.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!